

G OPEN ACCESS

Citation: Theilacker C, Diederich A-K, Otto A, Sava IG, Wobser D, Bao Y, et al. (2015) *Enterococcus faecalis* Glycolipids Modulate Lipoprotein-Content of the Bacterial Cell Membrane and Host Immune Response. PLoS ONE 10(7): e0132949. doi:10.1371/ journal.pone.0132949

Editor: Lynn E. Hancock, University of Kansas, UNITED STATES

Received: November 29, 2014

Accepted: June 21, 2015

Published: July 14, 2015

Copyright: © 2015 Theilacker et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the German Federal Ministry of Education and Research (BMBF 01 EO 0803).

Competing Interests: The authors have declared that no competing interests exist.

RESEARCH ARTICLE

Enterococcus faecalis Glycolipids Modulate Lipoprotein-Content of the Bacterial Cell Membrane and Host Immune Response

Christian Theilacker^{1,2®^a}*, Ann-Kristin Diederich^{2,3,6®}, Andreas Otto⁴, Irina G. Sava⁷, Dominique Wobser², Yinyin Bao², Katrin Hese¹, Melanie Broszat², Philipp Henneke^{1,5}, Dörte Becher⁴, Johannes Huebner^{2,3}

Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany,
Center for Infectious Disease and Travel Medicine, University Medical Center Freiburg, Freiburg,
Germany, 3 Division of Pediatric Infectious Diseases, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany, 4 Institute for Microbiology, Department of Microbial Physiology,
Ernst-Moritz-Arndt-University, Greifswald, Germany, 5 Center for Paediatrics and Adolescent Medicine,
University Medical Center Freiburg, Freiburg, Germany, 6 Department of Microbiology, Faculty of Biology,
Albert-Ludwigs-University, Freiburg, Germany, 7 Research Center for Nutrition and Food Science, Technical
University Munich, Freising, Germany

• These authors contributed equally to this work.

- ¤ Current address: Div. of Infectious Diseases & Hospital Epidemiology, University Hospital Basel,
- Petersgraben 4, 4031 Basel, Switzerland

* christian.theilacker@usb.ch

Abstract

In this study, we investigated the impact of the cell membrane composition of E. faecalis on its recognition by the host immune system. To this end, we employed an E. faecalis deletion mutant ($\Delta bgsA$) that does not synthesize the major cell membrane glycolipid diglycosyl-diacylglycerol (DGlcDAG). Proteomic analysis revealed that 13 of a total of 21 upregulated surface-associated proteins of *E. faecalis \Delta bgsA* were lipoproteins. This led to a total lipoprotein content in the cell membrane of 35.8% in ΔbgsA compared to only 9.4% in wildtype bacteria. Increased lipoprotein content strongly affected the recognition of $\Delta bgsA$ by mouse macrophages in vitro with an increased stimulation of TNF-α production by heatfixed bacteria and secreted antigens. Inactivation of the prolipoprotein diacylglycerol transferase (*Igt*) in $\Delta bgsA$ abrogated TNF- α induction by a $\Delta bgsA$ *Igt* double mutant indicating that lipoproteins mediate increased activation of mouse macrophages by $\Delta bgsA$. Heatfixed $\Delta bgsA$ bacteria, culture supernatant, or cell membrane lipid extract activated transfected HEK cells in a TLR2-dependent fashion; the same was not true of wild-type bacteria. In mice infected intraperitoneally with a sublethal dose of E. faecalis we observed a 70% greater mortality in mice infected with $\Delta bgsA$ compared with wild-type-infected mice. Increased mortality due to \DbgsA infection was associated with elevated plasma levels of the inflammatory cytokines TNF- α , IL-6 and MIP-2. In summary, our results provide evidence that an E. faecalis mutant lacking its major bilayer forming glycolipid DGlcDAG upregulates lipoprotein expression leading to increased activation of the host innate immune system and virulence in vivo.

Introduction

In invasive bacterial infections, host inflammation may vary from low-grade to a strong systemic response associated with multi-organ failure and severe sepsis. The differences in the host response are thought to result mainly from activation of the innate immune system by pathogen- and danger-associated molecular patterns. In Gram-positive sepsis, a variety of microbial compounds such as peptidoglycan and its derivatives, bacterial DNA, lipoteichoic acid, and lipoproteins are believed to activate the host immune system [1]. Numerous studies in mice have underlined the role of Toll-like receptor 2 (TLR2) as a major sensor of Gram-positive bacteria, yet its role in vivo is strongly dependent on the specific infectious microorganism [2-6]. In contrast, no clear association has been established between TLR2 variants and susceptibility to Gram-positive infection in humans [7,8].

Several TLR2 ligands have been identified in Gram-positive bacteria, including peptidoglycan, LTA, and lipoproteins/lipopeptides [9]. Studies with mutants of the lipoprotein-acyl transferase (*lgt*) gene and considerations regarding the structure-function relationship suggest that lipopeptides/lipoproteins are the predominant agonists of the TLR2/TLR6 dimer [10,11]. Lipoproteins/ lipopeptides are important amphiphiles of the cell membrane in Gram-positive bacteria. They are found both in the cell envelope and culture supernatant [12]. In *Mycobacterium tuberculosis*, membrane-derived vesicles have been described as a vehicle to release lipoproteins into the environment and similar vesicles have also been described for *S. aureus* [13,14]. Together with phospholipids, glycolipids, and lipoteichoic acid they constitute the lipid bilayer of the cell membrane.

We have previously studied the impact of cell membrane composition on the virulence of *E. faecalis* using mutants deficient in glycolipid biosynthesis. For this purpose we constructed two deletion mutants in *E. faecalis* strain 12030 ($\Delta bgsA$ and $\Delta bgsB$) that are defective in the glycosylation of glycolipids [15,16]. Inactivation of *bgsA* leads to a complete loss of DGlcDAG from the cell membrane and accumulation of high concentrations of its precursor molecule monoglycosyl-diacylglycerol (MGlcDAG) [15]. Inactivation of $\Delta bgsB$, on the other hand, results in a cell membrane devoid of glycolipids [16]. Both $\Delta bgsA$ and $\Delta bgsB$ elaborate a longer poly-glycerophosphate polymer of LTA than wild-type bacteria and show impaired biofilm formation and attachment to colonic epithelial cells. In a mouse bacteremia model, both mutants were cleared more rapidly from the bloodstream [15,16]. Interestingly, defects in glycolipid biosynthesis in $\Delta bgsA$ and $\Delta bgsB$ were not associated with changes in the bacterial cell shape or ultrastructure, in the growth rate, or in sensitivity to osmotic stress. This finding was surprising, since the ratio of the bilayer-forming DGlcDAG and the nonbilayer-prone MGlcDAG was shown to be critical for cell membrane architecture and curvature stress in studies using *Acholeplasma laidlawii* [17,18].

Here we examined the consequences of the altered glycolipid composition in $\Delta bgsA$ on the cell-surface proteome of the bacteria and studied the impact of these changes on the interaction between bacteria and the host immune system. For the investigation of the virulence of glycolipid-deficient *E. faecalis* strains we used a mouse peritonitis model that has been validated in several previous studies [19–22]. Our results show that in the absence of DGlcDAG, lipoprotein expression is upregulated in *E. faecalis*, which substantially increases the activation of TLR2 and virulence in vivo.

Materials and Methods

Bacterial strains, growth conditions, and medium

The bacterial strains and plasmids used in this study are listed in <u>Table 1</u>. Enterococci were cultured in tryptic soy broth (TSB, Merck), M17 broth (Difco Laboratories), Caso Bouillon (Carl

Table 1. Bacter	ial strains used a	and plasmids used	in this study.
-----------------	--------------------	-------------------	----------------

strain or plasmid	characterization	reference
strains		
E. faecalis 12030	Clinical isolate, strong biofilm producer	[54]
E. faecalis 12030∆bgsA	(EF2891) bsgA deletion mutant	[15]
E. faecalis 12030∆bgsB	(EF2890) <i>bsgB</i> deletion mutant	[25]
E. faecalis 12030∆lgt	(EF 1748) <i>lgt</i> deletion mutant	this study
E. faecalis 12030∆bgsA_lgt	double bgsA-lgt deletion mutant	this study
E. faecalis 12030∆bgsB_lgt	double bgsB-lgt deletion mutant	this study
Escherichia coli DH5α	Gram-negative cloning host	Invitrogen
Escherichia coli TOP10	Gram-negative cloning host	Invitrogen
plasmids		
pCASPER	Gram-positive, temperature-sensitive mutagenesis vector	55
pCRII-TOPO	Gram-negative cloning vector	Invitrogen
pCASPER/Δ <i>lgt</i>	pCASPER carrying a <i>lgt</i> deletion	this study

doi:10.1371/journal.pone.0132949.t001

Roth), or TSB plus 1% glucose (TSBG) as indicated. In addition, tryptic soy agar or M17 agar plates were used. *Escherichia coli* DH5α and TOP10 (Invitrogen) were cultivated aerobically in LB-broth. For cell culture stimulation studies, bacteria were grown in chemically defined medium (CDM) prepared from endotoxin-free water [23].

Construction of deletion mutant Δlgt

A non-polar deletion of a portion of gene lgt (EF1748 in E. faecalis V583, GenBank ID accession number NP_815451) was created using the method described by Cieslewicz et al., [24] with the following modifications: primers 1 and 2 (Table 2) were used to amplify a 503-bp fragment from the region upstream of gene lgt, and also the end part of EF1747. Primers 3 and 4 were used to amplify a 546-bp fragment downstream of the lgt gene and the beginning of EF1749. Primers 2 and 3 contain a 21-bp complementary sequence (underlined in Table 2). Overlap extension PCR was used to create a PCR product lacking a portion of gene EF1748. The resulting fragment was cloned into Gram-negative cloning vector pCRII-TOPO (Invitrogen) and cut with the restriction enzyme EcoRI (Invitrogen); the resulting fragment was then inserted into shuttle vector pCASPER containing a temperature-sensitive origin of replication. The resulting plasmid, pCASPER/ Δlgt , was transformed into *E. faecalis 12030* by electroporation, and integrants were selected at a non-permissive temperature (42°C) on TSA plates with kanamycin (1 mg/ml). A single colony was picked, and insertion of plasmid into the chromosome was confirmed by PCR. The integrant was passaged 10 times in liquid culture without antibiotic at the permissive temperature (30°C), and colonies were replica-plated to screen for loss of kanamycin resistance. The excision of the plasmid either creates a reconstituted wild-type strain or leads to

Table 2. Primers used in this study.

	name	sequence (5´-3´) ^a
1	pEF1748delF	CCTTGTTCGAGCCCTTTACTT
2	pEF1748OEF	ACTAGCGCGGCCGCTTGCTCCGTTCGTGGCAGCAATTGTTAT
3	pEF1748delR	ACGTCATGAACCTGTTTGGAG
4	pEF1748OER	GGAGCAAGCGGCCGCGCTAGTTAATCTTGCCATTGAAAAGCG

^aLinkers are underlined.

doi:10.1371/journal.pone.0132949.t002

an allelic replacement with the deleted sequence in the chromosome. The deletion mutant created was designated *E. faecalis* $12030 \Delta lgt$, containing a 507-bp (169 amino acids) in-frame deletion. The genotype was confirmed by PCR and automated sequencing.

Construction of a \Delta bgsA_lgt and \Delta bgsB_lgt double mutant

For construction of the double mutants $bgsA_lgt$ and $bgsB_lgt$ the plasmid pCASPER/ Δlgt was transformed into prepared electroporation-competent cells of *E. faecalis* 12030 $\Delta bgsA$ or $\Delta bgsB$ following the procedure described above for the construction of the single Δlgt deletion mutant.

Preparation of E. faecalis antigens for stimulation experiments

E. faecalis strains were grown for 16 h in CDM to stationary phase, collected by centrifugation and washed twice in phosphate buffered saline (PBS). The multiplicity of infection (MOI) for the cell culture experiments was calculated by quantification of colony-forming units (CFU) of serially diluted live bacteria of the respective strain on agar plates, with subsequent adjustment of the suspension of heat-fixed cells to the desired MOI. Cell culture supernatant was filtersterilized with a 0.2-µm membrane, dialyzed for 24 h against endotoxin-free water, and lyophilized. Bacteria were fixed at 65°C for 60 min. Extraction according to the method of Bligh and Dyer was used to obtain total cell membrane lipids as described previously [15,25]. The concentration of the supernatant and total lipid extracts in the stimulation experiments is expressed as weight per volume.

Lipoproteins were enriched from cell membrane fractions by phase-partitioning with Triton X-114 (TX114) [11,26,27]. To this end, bacterial cells were grown in CDM medium as described above and quantified by serial dilutions and viable counts after culture on agar plates. Bacterial cells were disrupted by vibration with glass beads as described previously [15]. Cell debris and glass beads were pelleted by centrifugation and the supernatant was diluted in TNbuffer (20 mM Tris, 100 mM NaCl, pH 8.0) and passed through a 0.2 µm membrane. For separation of the cell membrane fraction, the filtered supernatant was ultracentrifuged at 50,000 rpm at 4°C for 1 h. The supernatant was discarded and the cell membrane fraction redissolved in TN-buffer plus 2% TX114 (v/v) and incubated at 4°C for 2 h, followed by a second incubation step at 37°C for 30 min. The solution was centrifuged (6,000 rpm, 10 min, 37°C) for phase separation. The lower detergent-soluble phase was carefully collected. The detergent-soluble phase was further purified by adjusting the TX114 concentration to 2% and repeating the phase partitioning, as described above. For removal of TX114, the detergent phase was mixed with 90% ethanol, incubated at -20°C for 18 h and precipitated proteins were collected by centrifugation. After resuspension in TN-buffer the protein concentration of the lipoprotein extracts was determined photometrically and normalized to bacterial cfu.

Metabolic labeling, isolation of surface-associated proteins

Surface-associated proteins were isolated by biotin labeling and affinity chromatography. Proteins were quantified with the spike-in of a stable isotope-labeled standard. For metabolic labeling the method of Becher *et al.* was used with modifications [28]. *E. faecalis* 12030 wild-type and $\Delta bgsA$ were each grown separately in both labeled and unlabeled rich growth media for *E. coli*, (*E.coli*-OD5, Silantes) supplemented with 2% glucose, vitamins (p-amino benzoic acid, biotin, folic acid, niacinamide, pantothenate, riboflavin, thiamine), and nucleotides. Cultures were grown at 37°C for 18 h while shaking at 140 rpm. As an internal standard, equal volumes of wild-type and $\Delta bgsA$ grown to the same OD_{600nm} in ¹⁵N-labeled medium were mixed. Subsequently, equivalent OD units of wild-type and $\Delta bgsA$ cell culture grown in unlabeled medium were each mixed with the internal standard and centrifuged.

Cell pellets of wild-type and $\Delta bgsA$ were each washed once with PBS (pH 8) plus PMSF (1 mM). Cells (0.15 g) were resuspended in 1 ml PBS/PMSF, and Sulfo-N-hydroxysulfosuccinimide-disulfide-Biotin (Sulfo-NHS-SS-Biotin; Thermo Scientific) was added to produce a final concentration of 1 mM. The cell suspension was shaken carefully on ice for 1 h. After centrifugation, biotinylation was stopped by washing cells three times in 1 ml PBS plus 500 mM glycine. Next, cells were resuspended in 1 ml PBS and disrupted with glass beads (0.1 mm diameter) in two cycles at 6,800 rpm for 30 s using a ribolyser (Roche). To obtain cell membrane proteins, cell debris was washed six times with PBS and centrifuged at 45,000 rpm for 1 h at 4°C. Cell debris was resuspended in 0.4 ml PBS/I2-Iodoacetamide (5%) and homogenized with glass beads (0.1 mm diameter) using a ribolyser (6,800 rpm; 2x 30 s). To each sample 100 µl PBS plus 20% CHAPS and 20% Amidosulfobetaine-14 was added, homogenized in a ribolyser (6,800 rpm; 2 x 30 s) and shaken gently for 1 h at 20°C. Cell debris was removed again by centrifugation (14,000 rpm; 15 min; 4°C). Biotinylated proteins were recovered by incubation of the protein lysate with NeutrAvidin-agarose-beads equilibrated in PBS/Nonidet P40 (1%) for 1 h on ice while shaking. Unbound proteins were removed by washing beads four times with PBS/NP-40 plus 6% CHAPS and two times with 1 ml PBS/ NP-40 plus 2% SDS. For elution of bound proteins, the disulfide bond of Sulfo-NHS-SS-Biotin was cleaved by incubation with 5% β -mercaptoethanol in deionized water for 1 h at 20°C. NeutrAvidin-Agarose-Beads were removed by centrifugation and the supernatant was transferred to 8 ml acetone (-20°C). Elution buffer was once again added to each sample, centrifuged and the resulting supernatant was also added to the acetone-elution-buffer-mix. Proteins were precipitated with acetone overnight at -20°C. Precipitated proteins were centrifuged (8,500 rpm; 30 min; 4°C) and washed with ethanol (98%; 4°C). Finally, the pellet was dried in 6 M urea/2 M thiourea under vacuum (SpeedVac; Bachofer).

Protein identification and quantification by ESI-LC-MS/MS

Subsequent to preparation of the mixed and labeled protein extracts, samples were subjected to SDS-gel electrophoresis. Resulting gel lanes were cut into equidistant pieces, followed by tryptic in-gel digestion as described elsewhere [29]. The resulting proteolytic digests were subjected to LC-MS/MS analyses as described elsewhere [30]. In brief, peptides were applied to reversed-phase C_{18} chromatography on an EASYnLC system (Thermo Fisher) online coupled to an LTQ-Orbitrap mass spectrometer (Thermo Fisher). For LC-MS analyses a full survey scan in the Orbitrap (m/z 300–2000) with a resolution of 30,000 was followed by MS/MS experiments of the five most abundant precursor ions acquired in the linear trap quadrupole (LTQ) via collision-induced dissociation (CID).

Database searching for light and heavy extracts and subsequent quantitation were done as described in Otto *et al.* [30]. For unambiguous identification data, database searching by Sorcerer-Sequest (version 3.5) relied on an *E. faecalis* target-decoy protein sequence database (*E. faecalis* V583 (NC_004668.1) including a set of common contaminants). The following parameters were set for database searching: enzyme type, trypsin maximum of two missed trypsin cleavage sites; peptide tolerance, 10 ppm; tolerance for fragment ions, 1amu.; b- and y-ion series; variable modification, oxidation of methionine (15.99 Da). For database searches for ¹⁵N-labeled peptides, the mass shift of all amino acids completely labeled with ¹⁵N-nitrogen was taken into account. Relative quantification was carried out as described previously [31]. Protein identifications were considered significant for the biological system if the protein was identified in at least two out of three samples in wild type or the mutant. The crude search results served as the base for the further analysis using Census software to obtain quantitative data of ¹⁴N peaks (sample) and ¹⁵N peaks (standard) [32].

Relative quantification of surface-associated proteins by spectral counting

For estimation of relative proportions of proteins within the surface proteome of *E. faecalis*, the normalized spectral abundance factor (NSAF) for the light mass traces (¹⁴N) were calculated as described elsewhere [33]. For calculation of NSAF, spectra from raw data were extracted and searched as described above taking into account only light masses. Scaffold (version Scaffold_4.3.2, Proteome Software Inc.) was then used to validate MS/MS based peptide and protein identifications. Peptide identifications were only accepted if they exceeded specific database search engine thresholds. Sequest identifications required at least deltaCn scores of greater than 0.10 and XCorr scores of greater than 2.2, 3.3, and 3.8 for doubly, triply, and quadruply charged peptides, respectively. Protein identifications were accepted if they contained at least two identified peptides. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Calculation of NSAF was carried out as described elsewhere [34].

RAW 264.7 mouse macrophage stimulation

RAW 264.7 macrophages were seeded at a density of 1 x 10^5 cells/ml in 24-well dishes in endotoxin-free DMEM containing 10% fetal calf serum. Cultures were stimulated with either heatkilled bacteria, lyophilized supernatant or lipoprotein TX114-extracts from bacterial culture for 16 h at 37°C in a 5% humidified CO₂ environment. After the incubation period, cell culture supernatant was collected and TNF- α production measured by commercial ELISA (R&D Systems) according to the manufacturer's protocols. A commercial LPS preparation from *E. coli* 0111:B4 (Sigma Chemicals) was used as positive control.

Reporter gene analysis

HEK293 cells (Sigma Aldrich) and the stable cell line HEK-TLR2YFP were used in reporter gene studies as described [2]. In brief, cells were seeded into 96-well tissue-culture plates at a density of 5×10^5 cells/well. Cells were transiently transfected 16 hours later with an ELAM.luc reporter construct with TransIT-LT1 transfection reagent (Mirus Bio). Plasmid pcDNA was used to assure equal amounts of transfected DNA. The following day cells were incubated for 6 h with bacterial cells or cell wall extracts as indicated. After incubation, cultured cells were lysed in passive lysis buffer (Promega) and reporter gene activity was measured using a plate reader luminometer (MicroLumat Plus; Berthold).

Mouse peritonitis model

The virulence of *E. faecalis* strains was evaluated in a mouse peritonitis model. The mice were housed in groups of 5 per cage. All procedures were carried out between 8 a.m. and 18 p.m. in the animals home cage. Fourteen female BALB/C mice (Charles River Laboratories) 6–8 weeks old per group were assigned randomly to infection by intra-peritoneal injection of *E. faecalis* strains as indicated. The inoculum for the infection model was grown in TSB for 16 h to stationary phase, washed in PBS, adjusted to the desired concentration and injected intraperitoneally (i.p.) in 200 μ l of PBS. The bacterial inoculum was confirmed by plating serial dilutions on agar plates. Mice were monitored twice daily for mortality or signs of illness. If mice had reached an unconscious or moribund state they were euthanized by carbon dioxide inhalation and counted as dead. A moribund condition was defined as impaired mobility, the inability to reach food and water or to keep an upright position, labored breathing or cyanosis, or a hunched position for more than 48 h. Moribund mice were placed in a chamber and CO₂ was

introduced at a displacement rate approximately 20% of the chamber volume per min. The CO_2 flow was maintained for at least 1 minute after respiratory arrest of the animal. For quantification of bacterial counts and measurement of cytokines, mice (six per group) were sacrificed as described above. Peritoneal lavage fluid (PLF) was obtained by injecting 2 ml of sterile PBS with a 18-gauge needle. Blood was drawn under sterile precautions by cardiac puncture and transferred to heparin tubes. Next, the abdomen was opened, and the right kidney was harvested. All samples were directly placed on ice and processed immediately. The number of *E. faecalis* CFU in the PLF, blood, and kidney homogenate was determined. Kidneys were weighed and homogenized at 4°C in 2 ml of TSB with a tissue homogenizer. Serial 10-fold dilutions were made of each sample in TSB, 10 µl of each dilution was plated onto TSA plates and CFUs were enumerated after 18 h of incubation. The leukocytes in the PLF were counted as described elsewhere [22]. PLF supernatant and plasma were stored at -20°C until measurement of the cytokines.

Ethics statement

All animal experiments were performed in compliance with the German animal protection law (TierSchG). The mice were housed and handled in accordance with good animal practice as defined by FELASA and the national animal welfare body GV-SOLAS. The animal welfare committees of the University of Freiburg (Regierungspraesidium Freiburg Az 35/9185.81/G-07/15) approved all animal experiments. The institutional review board of the University of Freiburg approved the study protocol.

Statistical analysis

Statistical significance for two-way comparisons was determined by an unpaired t-test as indicated. Analysis of variance (ANOVA) for multigroup comparisons was used on log-transformed data, and the Tukey's multiple-comparison test was used for posthoc analysis for pairwise comparisons. Survival data were compared using the log-rank (Mantel-Cox) test. To identify the up- and downregulated proteins of the mutant compared to the wild-type, the log2 ratio of each protein quantification was calculated, subtracting the median log2 ratio of the replicates of the wild-type from that of the mutant. The relative quantification of proteins by spectral counting was deemed reliable when its ratio was ascertained in two replicates with not less than two peptides in at least one of the replicates [35]. Statistical results were calculated using the Prism 3 software package. Statistical significance for the NSAF values (mutant versus wildtype) was determined by a t-test in the software Scaffold (version Scaffold_4.3.2, Proteome Software Inc., Portland, OR) with a significance threshold alpha = 0.05.

Results

Analysis of enterococcal surface-associated proteins by the proteomics approach

To gain insight into the protein composition of the enterococcal cell-surface, wild-type bacteria and $\Delta bgsA$ surface-exposed proteins were biotinylated and purified by affinity chromatography prior to SDS-PAGE followed by in-gel digestion (IGD) and analysis by LC-MS/MS (GeLC-MS). Before surface proteins were selectively coupled to Sulfo-NHS-SS-Biotin, ¹⁴N¹⁵N metabolic protein labeling was performed during cultivation in CDM. Biotin-labeled proteins were purified by affinity-chromatography and eluted by cleavage of the disulfide bond of the Sulfo-NHS-SS-Biotin by reduction. This approach led to the unambiguous identification of a total of 210 proteins from wildtype bacteria in 2/3 replicates (<u>S1 Table</u>). Determined by the theoretical prediction rules of subcellular localization (reference 53, 36 and the LocateP DataBase was used (<u>http://www.cmbi.ru.</u> <u>nl/locatep-db/cgi-bin/locatepdb.py</u>)) the surface proteome fraction included 23 lipoproteins, 16 membrane proteins, and seven extracellular proteins containing a signal peptide. One hundred and sixty-four of the biotinylated proteins obtained were annotated with a cytoplasmic subcellular localization.

In \Delta bgsA the production of lipoproteins is upregulated

The altered composition of cell membrane glycolipids in $\Delta bgsA$ led to a profound change in the pattern of surface-associated proteins as compared to isogenic wild-type *E. faecalis*. A total of 88 proteins were significantly up- or downregulated proteins in $\Delta bgsA$ according to the statistical testing. Forty showed a significantly increased amount in $\Delta bgsA$ compared with wild-type bacteria, while 48 proteins were decreased (Table 3). Twenty-one predicted surface-associated proteins were upregulated in $\Delta bgsA$. Of those, 13 were predicted to be lipoproteins, six cell membrane proteins and two extracellular proteins (Fig 1). Only six of the downregulated proteins were surface-associated proteins. Strikingly, lipoproteins represented 35.8% of the surface-associated proteins of $\Delta bgsA$ compared to only 9.4% in wild-type bacteria as quantified by spectral abundance factors (detailed information see S2 Table). Of the five most overexpressed surface-associated proteins, all were lipoproteins and they were upregulated 1.95–12.22-fold in $\Delta bgsA$ compared to wild type bacteria (Table 3). Altogether, our data suggest that the inactivation of *bgsA* disturbs the equilibrium in the cell membrane that in consequence leads to an increased lipoprotein content.

$\Delta bgsA$ promotes vigorous activation of RAW 264.7 mouse macrophages

To evaluate the effect of the altered cell-surface composition of $\Delta bgsA$ on inflammatory responses in vitro, we stimulated RAW 264.7 macrophages in the presence of live and heatfixed *E. faecalis* and measured TNF- α in the cell culture supernatant after 3 h (live bacteria) and 16 h (heat-fixed bacteria and supernatant). In addition to $\Delta bgsA$ and wild-type bacteria, we used $\Delta bgsB$ as a second mutant defective in glycolipid biosynthesis in these experiments. At multiplicities of infection between 1:1 and 10:1, $\Delta bgsA$ induced significantly higher TNF- α concentrations compared to wild-type bacteria and $\Delta bgsB$, respectively (Fig 2A and 2B).

Staphylococcus aureus lipoproteins are known to be released during growth into the culture medium [12]. We therefore also stimulated RAW 264.7 macrophages with dialyzed culture supernatant of *E. faecalis* strains. Supernatant from $\Delta bgsA$ was a potent inducer of TNF- α production of RAW 264.7 cells in vitro (Fig 2C). While culture supernatant of wild-type bacteria was inactive even at concentrations as high as 10,000 ng/ml (dry weight per volume), $\Delta bgsA$ stimulated TNF- α production at concentrations a 100-fold lower (Fig 2). Low amounts of TNF- α were also induced by cell culture supernatant from $\Delta bgsB$ (Fig 2). Together with the proteome analysis, these results demonstrate that lack of DGlcDAG in the cell membrane of $\Delta bgsA$ not only changes the composition of cell-surface proteome, but also enhances the activation of innate immunity.

Lipoprotein-enriched cell membrane fractions of $\Delta bgsA$ but not wild-type cells stimulate TNF- α production of RAW 264.7 macrophages

Due to their amphiphilic properties, lipoproteins can be purified from cell membrane fractions by the detergent Triton X-114 [11,26]. MS-shotgun analysis of Triton-extracted total



Table 3. Surface-associated proteins present in significantly different amounts in $\Delta bgsA$ compared to the wild-type. The log2ratio depicts the change of $\Delta bgsA$ compared to the wild-type.

EF304112.222Pheromone binding proteinlipoproteinEF16413.114Iron compound ABC transporter, iron compound binding proteinlipoproteinEF15342.870Peptidyl prolyl cis/trans isomeraselipoproteinEF31982.258Lipoprotein. YaeC familylipoproteinEF13542.230Pyruvate dehydrogenase complex. E1 component. beta subunitcytoplasmicEF13532.207Pyruvate dehydrogenase complex. E1 component. alpha subunitcytoplasmicEF21911.983dTDP-4-dehydrorhamnose reductasecytoplasmicEF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF21561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	Protein accession number	log2 (ΔbgsA/wt)	Annotation	Localization ^a
EF16413.114Iron compound ABC transporter, iron compound binding proteinlipoproteinEF15342.870Peptidyl prolyl cis/trans isomeraselipoproteinEF31982.258Lipoprotein. YaeC familylipoproteinEF13542.230Pyruvate dehydrogenase complex. E1 component. beta subunitcytoplasmicEF13532.207Pyruvate dehydrogenase complex. E1 component. alpha subunitcytoplasmicEF21911.983dTDP-4-dehydrorhamnose reductasecytoplasmicEF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF12561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF3041	12.222	Pheromone binding protein	lipoprotein
EF15342.870Peptidyl prolyl cis/trans isomeraselipoproteinEF31982.258Lipoprotein. YaeC familylipoproteinEF13542.230Pyruvate dehydrogenase complex. E1 component. beta subunitcytoplasmicEF13532.207Pyruvate dehydrogenase complex. E1 component. alpha subunitcytoplasmicEF21911.983dTDP-4-dehydrorhamnose reductasecytoplasmicEF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF12121.828Transcriptional regulator LytRcell membraneEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF1641	3.114	Iron compound ABC transporter, iron compound binding protein	lipoprotein
EF31982.258Lipoprotein. YaeC familylipoproteinEF13542.230Pyruvate dehydrogenase complex. E1 component. beta subunitcytoplasmicEF13532.207Pyruvate dehydrogenase complex. E1 component. alpha subunitcytoplasmicEF21911.983dTDP-4-dehydrorhamnose reductasecytoplasmicEF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF12121.828Transcriptional regulator LytRcell membraneEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF1534	2.870	Peptidyl prolyl cis/trans isomerase	lipoprotein
EF13542.230Pyruvate dehydrogenase complex. E1 component. beta subunitcytoplasmicEF13532.207Pyruvate dehydrogenase complex. E1 component. alpha subunitcytoplasmicEF21911.983dTDP-4-dehydrorhamnose reductasecytoplasmicEF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF12121.828Transcriptional regulator LytRcell membraneEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF3198	2.258	Lipoprotein. YaeC family	lipoprotein
EF13532.207Pyruvate dehydrogenase complex. E1 component. alpha subunitcytoplasmicEF21911.983dTDP-4-dehydrorhamnose reductasecytoplasmicEF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF12121.828Transcriptional regulator LytRcell membraneEF21561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF1354	2.230	Pyruvate dehydrogenase complex. E1 component. beta subunit	cytoplasmic
EF21911.983dTDP-4-dehydrorhamnose reductasecytoplasmicEF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF12121.828Transcriptional regulator LytRcell membraneEF21561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF1353	2.207	Pyruvate dehydrogenase complex. E1 component. alpha subunit	cytoplasmic
EF30821.955Iron compound ABC transporter. substrate binding proteinlipoproteinEF11111.842Signal peptidase Icell membraneEF12121.828Transcriptional regulator LytRcell membraneEF21561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF2191	1.983	dTDP-4-dehydrorhamnose reductase	cytoplasmic
EF11111.842Signal peptidase Icell membraneEF12121.828Transcriptional regulator LytRcell membraneEF21561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF3082	1.955	Iron compound ABC transporter. substrate binding protein	lipoprotein
EF12121.828Transcriptional regulator LytRcell membraneEF21561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF1111	1.842	Signal peptidase I	cell membrane
EF21561.813Uncharacterized proteinextracellularEF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF1212	1.828	Transcriptional regulator LytR	cell membrane
EF30621.768Cell shape determining protein MreCextracellularEF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF2156	1.813	Uncharacterized protein	extracellular
EF31201.740Serine threonine protein kinasecytoplasmicEF30371.602Glutamyl aminopeptidasecytoplasmic	EF3062	1.768	Cell shape determining protein MreC	extracellular
EF3037 1.602 Glutamyl aminopeptidase cytoplasmic	EF3120	1.740	Serine threonine protein kinase	cytoplasmic
	EF3037	1.602	Glutamyl aminopeptidase	cytoplasmic
EF1677 1.601 Lipoprotein. putative lipoprotein	EF1677	1.601	Lipoprotein. putative	lipoprotein
EF1340 1.562 Pheromone cAM373 lipoprotein lipoprotein	EF1340	1.562	Pheromone cAM373 lipoprotein	lipoprotein
EF11911.526DegV family proteincytoplasmic	EF1191	1.526	DegV family protein	cytoplasmic
EF1759 1.491 Phosphate ABC transporter. phosphate binding protein lipoprotein	EF1759	1.491	Phosphate ABC transporter. phosphate binding protein	lipoprotein
EF3027 1.420 Serine protease DO cell membrane	EF3027	1.420	Serine protease DO	cell membrane
EF1523 1.324 Conserved domainI protein cytoplasmic	EF1523	1.324	Conserved domainl protein	cytoplasmic
EF2656 1.315 Flavoprotein family protein cytoplasmic	EF2656	1.315	Flavoprotein family protein	cytoplasmic
EF0176 1.300 Basic membrane protein family lipoprotein	EF0176	1.300	Basic membrane protein family	lipoprotein
EF1416 1.201 Glucose-6-phosphate isomerase cytoplasmic	EF1416	1.201	Glucose-6-phosphate isomerase	cytoplasmic
EF2697 1.159 Conserved domain protein cell membrane	EF2697	1.159	Conserved domain protein	cell membrane
EF1753 1.141 Uncharacterized protein cytoplasmic	EF1753	1.141	Uncharacterized protein	cytoplasmic
EF1045 1.111 6-phosphofructokinase cytoplasmic	EF1045	1.111	6-phosphofructokinase	cytoplasmic
EF0761 1.097 Amino acid ABC transporter. amino acid binding permease protein cell membrane	EF0761	1.097	Amino acid ABC transporter. amino acid binding permease protein	cell membrane
EF2496 1.085 Lipoprotein lipoprotein	EF2496	1.085	Lipoprotein	lipoprotein
EF0685 1.082 Foldase protein PrsA cell membrane	EF0685	1.082	Foldase protein PrsA	cell membrane
EF0784 1.079 S-adenosylmethionine synthase cytoplasmic	EF0784	1.079	S-adenosylmethionine synthase	cytoplasmic
EF0949 1.040 Phosphotransacetylase cytoplasmic	EF0949	1.040	Phosphotransacetylase	cytoplasmic
EF26080.904ATP synthase subunit betacytoplasmic	EF2608	0.904	ATP synthase subunit beta	cytoplasmic
EF26100.903ATP synthase subunit alphacytoplasmic	EF2610	0.903	ATP synthase subunit alpha	cytoplasmic
EF0863 0.887 Glycine betaine carnitine choline ABC transporter. glycine betaine carnitine choline binding lipoprotein protein	EF0863	0.887	Glycine betaine carnitine choline ABC transporter. glycine betaine carnitine choline binding protein	lipoprotein
EF2609 0.794 ATP synthase gamma chain cytoplasmic	EF2609	0.794	ATP synthase gamma chain	cytoplasmic
EF1355 0.793 Pyruvate dehydrogenase complex E2 component. dihydrolipoamide acetyltransferase cytoplasmic	EF1355	0.793	Pyruvate dehydrogenase complex E2 component. dihydrolipoamide acetyltransferase	cytoplasmic
EF3255 0.637 Thiamin biosynthesis lipoprotein ApbE. putative lipoprotein	EF3255	0.637	Thiamin biosynthesis lipoprotein ApbE. putative	lipoprotein
EF1961 0.478 Enolase cytoplasmic	EF1961	0.478	Enolase	cytoplasmic
EF2549 0.473 Uracil phosphoribosyltransferase cytoplasmic	EF2549	0.473	Uracil phosphoribosyltransferase	cytoplasmic
EF2903 0.190 ABC transporter. substrate binding protein lipoprotein	EF2903	0.190	ABC transporter. substrate binding protein	lipoprotein

(Continued)

Table 3. (Continued)

EF3258 -0.569 Phoromone AD1 lipoprotein Ipoprotein EF1484 -0.577 Roboomal protein S1 Optoplasmic EF1493 -0.580 Conserved domain protein Optoplasmic EF1493 -0.580 Abnc TA family protein Optoplasmic EF1384 -0.607 Optoplasmic Optoplasmic EF1384 -0.671 Optoplasmic Ef138 Optoplasmic EF1384 -0.671 Optoplasmic Ef138 Optoplasmic EF1384 -1.051 Unportein, putative extracellular EF1384 -1.051 Upoprotein, putative extracellular EF1384 -1.051 ND optome protein S18 optoplasmic EF1384 -1.051 ND optome protein S18 optoplasmic EF1384 -1.053 op	Protein accession number	log2 (∆bgsA/wt)	Annotation	Localization ^a
EF1548 0.577 Fibosomal protein S1 cytoplasmic EF1402 0.508 Conserved domain protein cytoplasmic EF1402 0.502 DNA binding response regulator VicR cytoplasmic EF1384 0.607 Cysterine synthase cytoplasmic EF1384 0.607 Cysterine synthase cytoplasmic EF1384 0.607 Cysterine synthase cytoplasmic EF1384 0.667 Conserve protein cytoplasmic EF1384 0.667 Conserve protein cytoplasmic EF1385 0.930 Chaperone protein cytoplasmic EF1385 0.939 Prospotypolycerate kinase cytoplasmic EF1385 0.952 Prospotypolycerate kinase cytoplasmic EF1382 1.017 Trigger factor cytoplasmic EF1522 1.118 RNA polymenase signa factor RpoD cytoplasmic EF1323 1.174 3083 ribosomal protein S9 cytoplasmic EF2325 1.330 Aderyytek kinase cytoplasmic EF2326 <td>EF3256</td> <td>-0.569</td> <td>Pheromone cAD1 lipoprotein</td> <td>lipoprotein</td>	EF3256	-0.569	Pheromone cAD1 lipoprotein	lipoprotein
EF1402 -0.580 Conserved domain protein cytoplasmic EF1133 -0.590 AhpC TSA family protein cytoplasmic EF1234 -0.600 AhpC TSA family protein cytoplasmic EF1354 -0.607 Cysteine synthase cytoplasmic EF1358 -0.607 Cysteine synthase cytoplasmic EF1374 -0.606 Cell division protein FisZ cytoplasmic EF1378 -0.671 Oxidoreduclase. aldo-keto reduclase family cytoplasmic EF1378 -0.674 Chapterone protein CytB cytoplasmic EF1360 -1.092 Proken/oglycerate kinase cytoplasmic EF1560 -1.012 Uncharcetized protein cytoplasmic EF0344 -1.059 protein. putative extracellular EF0344 -1.051 Lipoprotein. cytoplasmic EF0344 -1.051 Lipoprotein Signa factor RpoD cytoplasmic EF0344 -1.051 Lipoprotein Signa factor RpoD cytoplasmic EF0344 -1.174 Ribosomal protein Sig cytoplasmic	EF1548	-0.577	Ribosomal protein S1	cytoplasmic
EF1193 -0.592 DNA binding response regulator VicR cytoplasmic EF2332 -0.600 AhpC TSA family protein cytoplasmic EF1384 -0.607 Cystane synthase cytoplasmic EF1987 -0.606 Cell division protein PisZ cytoplasmic EF1383 -0.871 Oxidorductase. aldo keto reductase family cytoplasmic EF1383 -0.934 Chaperone protein CytoB cytoplasmic EF183 -0.992 Phosphoglycerate kinase cytoplasmic EF1863 -1.012 Uncharaclerized protein cytoplasmic cytoplasmic EF1980 -1.012 Uncharaclerized protein cytoplasmic cytoplasmic EF152 -1.118 NRA polymerase sigma factor RpoD cytoplasmic cytoplasmic EF152 -1.117 Trigger factor Ts cytoplasmic cytoplasmic EF124 -1.236 ATP synthase opsilon chain cytoplasmic cytoplasmic EF2320 -1.334 Elongation factor Ts cytoplasmic cytoplasmic EF2321 -1.348	EF1402	-0.580	Conserved domain protein	cytoplasmic
EP2932 -0.600 AhpC TSA family protein cytoplasmic EF1584 -0.607 Cysteine synthase cytoplasmic EF1097 -0.606 Cell division protein F1s2 cytoplasmic EF1138 -0.817 Oxidoreductase, aldo-keto reductase family cytoplasmic EF1138 -0.817 Oxidoreductase, aldo-keto reductase family cytoplasmic EF1360 -0.932 Phosphogiverate kinase cytoplasmic EF1560 -0.101 Uncharacterizad protein cytoplasmic EF1034 -1.051 Lipoprotein, putative extracellular EF0354 -1.017 Trigger factor cytoplasmic EF1754 -1.107 Trigger factor cytoplasmic EF1754 -1.117 Ribosomal subuti fitace protein cytoplasmic EF1754 -1.128 ATP synthase signa factor Pp0 cytoplasmic EF2807 -1.236 ATP synthase signa factor Pp0 cytoplasmic EF2807 -1.384 Probable transcriptional regulatory protein cytoplasmic EF2807 -1.384 A	EF1193	-0.592	DNA binding response regulator VicR	cytoplasmic
EF1584 -0.607 Cysteine synthase cytoplasmic EF0997 -0.698 Cell division protein FIsZ cytoplasmic EF1138 -0.671 Oxidoreductase, aldo-keto reductase family cytoplasmic EF1235 -0.934 Chaperone protein cµtalwe extracellular EF1963 -0.992 Phosphoglycerate kinase cytoplasmic EF1963 -1.012 Uncharacterized protein cytoplasmic EF1964 -1.051 Lipoprotein, putative cytoplasmic EF1975 -1.107 Trigger factor cytoplasmic EF1972 -1.117 RIbosomal subunt interface protein cytoplasmic EF1972 -1.117 RIbosomal subunt interface protein cytoplasmic EF1974 -1.171 RIbosomal protein Signa factor RpoD cytoplasmic EF2607 -1.232 ATP synthase egoino chain cytoplasmic EF2612 -1.382 ATP synthase subunt b cytoplasmic EF2612 -1.382 ATP synthase subunt b cytoplasmic EF2612 -1.382 ATP synthase sub	EF2932	-0.600	AhpC TSA family protein	cytoplasmic
EP0997 -0.696 Cell division protein FisZ cytoplasmic EF1138 -0.871 Oxidoredctase. aldo-kato reductase family cytoplasmic EF1255 -0.934 Chaperone protein CtpB cytoplasmic EF1244 -0.956 General stress protein. putative extracellular EF1560 -1.012 Uncharacterized protein cytoplasmic EF3054 -1.051 Lipoprotein. putative extracellular EF0944 -1.059 protein. putative cytoplasmic EF7054 -1.177 Trigger factor cytoplasmic EF7054 -1.178 Bixoportein. putative cytoplasmic EF7054 -1.174 305 ribosomal protein S9 cytoplasmic EF2307 -1.334 Elongation factor TS cytoplasmic EF2397 -1.344 Elongation factor TS cytoplasmic EF2307 -1.344 Elongation factor P cytoplasmic EF2312 -1.344 Elongation factor P cytoplasmic EF2326 -1.653 mc-Or family protein cytoplasmic	EF1584	-0.607	Cysteine synthase	cytoplasmic
EF1138 -0.871 Oxidoreductase, aido-keto reductase family cytoplasmic EF2355 -0.934 Chaperone protein ClpB cytoplasmic EF1744 -0.956 General stress protein, putative cytoplasmic EF1860 -1.012 Uncharacterized protein cytoplasmic EF3054 -1.051 Lipoprotein, putative cytoplasmic EF0915 -1.017 Trigger factor cytoplasmic EF0715 -1.107 Trigger factor cytoplasmic EF122 -1.118 RNA polymerase sigma factor RpoD cytoplasmic EF1230 -1.171 Ribosomal protein cytoplasmic EF2320 -1.188 NA polymerase sigma factor RpoD cytoplasmic EF2320 -1.171 Ribosomal protein S9 cytoplasmic EF2320 -1.236 ATP synthase epsilon chain cytoplasmic EF2321 -1.332 ATP synthase subunit b cytoplasmic EF2323 -1.414 Kaa-his dipeptidase cytoplasmic EF2326 -1.330 Aderyyntke kinase cytoplasmi	EF0997	-0.696	Cell division protein FtsZ	cytoplasmic
EP2355 -0.934 Chaperone protein CIpB cytoplasmic EF1744 -0.956 General stress protein, putative extracellular EF1963 -0.992 Phosphoglverate kinase cytoplasmic EF1863 -1.012 Uncharacterized protein cytoplasmic EF3054 -1.051 Lipoprotein, putative cytoplasmic EF0715 -1.107 Trigger factor cytoplasmic EF1724 -1.117 Ribosomal subunit interface protein cytoplasmic EF3230 -1.124 BNA polymerase sigma factor RpoD cytoplasmic EF3230 -1.124 BNA polymerase sigma factor RpoD cytoplasmic EF3230 -1.124 BOS ribosomal protein S9 cytoplasmic EF2397 -1.236 ATP synthase epsilon chain cytoplasmic EF2392 -1.384 Adenylate kinase cytoplasmic EF2305 -1.425 Kabis transcriptional regulatory protein cytoplasmic EF2305 -1.442 Elongation factor P cytoplasmic EF2305 -1.442 Elongation factor P	EF1138	-0.871	Oxidoreductase. aldo-keto reductase family	cytoplasmic
EF1744 -0.956 General stress protein. putative extracellular EF1963 -0.992 Phosphoglycerate kinase cytoplasmic EF1960 1.012 Uncharacterized protein cytoplasmic EF1950 -1.051 Lipoprotein. putative extracellular EF034 -1.051 Lipoprotein. putative extracellular EF035 -1.107 Trigger factor cytoplasmic EF1520 -1.118 RNA polymerase sigma factor RpoD cytoplasmic EF2330 -1.174 Biosomal subunit inefrace protein cytoplasmic EF2320 -1.236 ATP synthase epsilon chain cytoplasmic EF2321 -1.380 Adenylate kinase cytoplasmic EF2322 -1.380 Adenylate kinase cytoplasmic EF2323 -1.342 ATP synthase subunit b cytoplasmic EF2324 -1.432 Xaa-his dipeptidase cytoplasmic EF2325 -1.342 ATP synthase subunit b cytoplasmic EF2326 -1.342 Xaa-his dipeptidase cytoplasmic	EF2355	-0.934	Chaperone protein ClpB	cytoplasmic
EF1963 -0.982 Phosphoglycerate kinase cytoplasmic EF1560 -1.012 Uncharacterized protein cytoplasmic EF1560 -1.012 Uncharacterized protein cytoplasmic EF0954 -1.051 Lipoprotein cytoplasmic EF0715 -1.107 Trigger factor cytoplasmic EF1522 -1.118 RNA polymerase sigma factor RpoD cytoplasmic EF1323 -1.174 Ribosomal protein S9 cytoplasmic EF2807 -1.363 ATP synthase opsicon chain cytoplasmic EF2812 -1.380 Aderylate kinase cytoplasmic EF2812 -1.384 Probable transcriptional regulatory protein cytoplasmic EF2812 -1.384 Probable transcription transcription transcription cytoplasmic EF087 -1.412 Xaa-his dipeptidase cytoplasmic <td>EF1744</td> <td>-0.956</td> <td>General stress protein. putative</td> <td>extracellular</td>	EF1744	-0.956	General stress protein. putative	extracellular
EF1560 -1.012 Uncharacterized protein cytoplasmic EF3054 -1.051 Lipoprotein, putative lipoprotein EF0304 -1.059 protein, putative extracellular EF0315 -1.107 Trigger factor cytoplasmic EF1522 -1.118 RNA polymerase sigma factor RpoD cytoplasmic EF1234 -1.171 Ribsoomal subunit interface protein cytoplasmic EF2303 -1.174 305 ribosomal protein S9 cytoplasmic EF2327 -1.236 ATP synthase epsilon chain cytoplasmic EF2287 -1.381 Elongation factor Ts cytoplasmic EF22812 -1.382 ATP synthase subunit b cytoplasmic EF2612 -1.384 Probable transcriptional regulatory protein cytoplasmic EF2613 -1.442 Elongation factor P cytoplasmic EF0671 -1.442 Elongation factor P cytoplasmic EF070 -1.643 Omithine carbamoyltransferase. catabolic cytoplasmic EF0705 -1.613 Omithine carbamoyltran	EF1963	-0.992	Phosphoglycerate kinase	cytoplasmic
EF3054-1.051Lipoprotein, putativelipoproteinEF0944-1.059protein, putativeextracellularEF0715-1.107Trigogr tactorcytoplasmicEF1522-1.118RNA polymerase sigma factor RpoDcytoplasmicEF1744-1.174Ribosomal subunt interface proteincytoplasmicEF2320-1.124Ribosomal subunt interface proteincytoplasmicEF2607-1.236ATP synthase epsilon chaincytoplasmicEF2280-1.380Adenylate kinasecytoplasmicEF22612-1.380Adenylate kinasecytoplasmicEF2626-1.384Probable transcriptional regulatory proteincytoplasmicEF2636-1.384Probable transcriptional regulatory proteincytoplasmicEF0271-1.442Elongation factor PcytoplasmicEF0287-1.442Elongation factor PcytoplasmicEF0287-1.648OS ribosomal protein L1cytoplasmicEF0297-1.648Os ribosomal protein L1cytoplasmicEF0297-1.649Transcriptional regulatory protein musGcytoplasmicEF0297-1.648Os ribosomal protein L1 12cytoplasmicEF0297-1.649Transcriptional regulatory protein musGcytoplasmicEF0297-1.648Uncharacterized proteincytoplasmicEF029-1.639PTS system. mannose specific IIAB componentscytoplasmicEF029-1.649Transcription termination antitermination protein nusGcytoplasmic	EF1560	-1.012	Uncharacterized protein	cytoplasmic
EF0844 -1.059 protein. putative extracellular EF0715 -1.107 Trigger factor cytoplasmic EF1522 -1.118 RNA polymerses sigma factor RpoD cytoplasmic EF1424 -1.171 Ribosomal putein S9 cytoplasmic EF2807 -1.236 ATP synthase epsilon chain cytoplasmic EF2807 -1.344 Elongation factor Ts cytoplasmic EF2807 -1.344 Elongation factor Ts cytoplasmic EF2806 -1.384 Probable transcriptional regulatory protein cytoplasmic EF2866 -1.384 Probable transcriptional regulatory protein cytoplasmic EF0671 -1.442 Elongation factor P cytoplasmic EF0287 -1.448 50S ribosomal protein L1 cytoplasmic EF0105 -1.613 Omithine carbamoyltransferase, catabolic cytoplasmic EF0215 -1.624 JoS ribosomal protein L7 L12 cytoplasmic EF0215 -1.639 Transcription termination antitermination protein nusG cytoplasmic EF0210 -1	EF3054	-1.051	Lipoprotein. putative	lipoprotein
EF0715 -1.107 Trigger factor cytoplasmic EF1522 -1.118 RNA polymerase sigma factor RpoD cytoplasmic EF1754 -1.117 Ribosomal protein Spot cytoplasmic EF2300 -1.128 ATP synthase epsilon chain cytoplasmic EF2307 -1.380 ATP synthase epsilon chain cytoplasmic EF2307 -1.382 ATP synthase subunit b cytoplasmic EF2612 -1.382 ATP synthase subunit b cytoplasmic EF2612 -1.382 ATP synthase subunit b cytoplasmic EF2614 -1.412 Xaa-his dipeptidase cytoplasmic EF2615 -1.424 Elongation factor P cytoplasmic EF0271 -1.424 Elongation factor P cytoplasmic EF0287 -1.442 Elongation factor P cytoplasmic EF0278 -1.643 Omithine carbamoyltransferase. catabolic cytoplasmic EF0105 -1.613 Omithine carbamoyltransferase. catabolic cytoplasmic EF0270 -1.628 Uncharacterized protein cytoplasmic EF0270 -1.639 PTS system. mann	EF0944	-1.059	protein. putative	extracellular
EF1522-1.118RNA polymerase sigma factor RpoDcytoplasmicEF1764-1.171Ribosomal subunit interface proteincytoplasmicEF3330-1.17430S ribosomal protein S9cytoplasmicEF2807-1.236ATP synthase epsilon chaincytoplasmicEF2927-1.314Elongation factor TscytoplasmicEF2812-1.382ATP synthase subunit bcytoplasmicEF2812-1.384Probable transcriptional regulatory proteincytoplasmicEF2816-1.384Probable transcriptional regulatory proteincytoplasmicEF0827-1.442Elongation factor PcytoplasmicEF0827-1.442Elongation factor PcytoplasmicEF0837-1.442Elongation factor PcytoplasmicEF0845-1.655mC-Ohr family proteincellEF015-1.613Omithine carbamoyltransferase, cataboliccytoplasmicEF070-1.628Uncharacterized proteincytoplasmicEF2719-1.64250S ribosomal protein L1cytoplasmicEF2715-1.64250S ribosomal protein IC 12cytoplasmicEF2719-1.64250S ribosomal protein IC 12cytoplasmicEF2719-1.846Gls24 pro	EF0715	-1.107	Trigger factor	cytoplasmic
EF1764-1.171Ribosomal protein S9cytoplasmicEF3230-1.17430S ribosomal protein S9cytoplasmicEF2607-1.236ATP synthase epsilon chaincytoplasmicEF2237-1.314Elongation factor TscytoplasmicEF0228-1.380Adenylate kinasecytoplasmicEF2617-1.382ATP synthase subunit bcytoplasmicEF2666-1.384Probable transcriptional regulatory proteincytoplasmicEF0271-1.412Xaa-his dipeptidasecytoplasmicEF0287-1.442Elongation factor PcytoplasmicEF0278-1.655mc-Ohr family proteincytoplasmicEF0453-1.655mc-Ohr family proteincytoplasmicEF0700-1.610Omithine carbamoyltransferase. cataboliccytoplasmicEF0700-1.628Uncharacterized proteincytoplasmicEF0700-1.639PTS system, mannose specific IIAB componentscytoplasmicEF0709-1.64250S ribosomal protein L7 L12cytoplasmicEF0709-1.689Transcription termination antitermination protein nusGcytoplasmicEF0719-1.84630S ribosomal protein S8cytoplasmicEF0709-1.84630S ribosomal protein L25cytoplasmicEF0709-1.896Gis24 proteincytoplasmicEF0719-1.846S0S ribosomal protein L25cytoplasmicEF0729-1.896SioS ribosomal protein L25cytoplasmicEF032-2.036Su5 YioD xrdC YmC fa	EF1522	-1.118	RNA polymerase sigma factor RpoD	cytoplasmic
EF3230-1.17430S ribosomal protein S9cytoplasmicEF2807-1.236ATP synthase epsilon chaincytoplasmicEF2397-1.314Elongation factor TscytoplasmicEF2612-1.382Adenylate kinasecytoplasmicEF2612-1.384Probable transcriptional regulatory proteincytoplasmicEF2666-1.384Probable transcriptional regulatory proteincytoplasmicEF0671-1.442Elongation factor PcytoplasmicEF0672-1.442Elongation factor PcytoplasmicEF0673-1.605mc-Ohr family proteincellEF0674-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0750-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0770-1.628Uncharacterized proteincytoplasmicEF0709-1.629PTS system. mannose specific IIAB componentscytoplasmicEF2719-1.64250S ribosomal protein LT L12cytoplasmicEF2729-1.689Transcription HPrcytoplasmicEF2729-1.689Transcription HPrcytoplasmicEF2719-1.64430S ribosomal protein LT L12cytoplasmicEF2719-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF2719-1.84630S ribosomal protein L25cytoplasmicEF0200-1.93850S ribosomal protein L25cytoplasmicEF034-2.132Sols ribosomal	EF1764	-1.171	Ribosomal subunit interface protein	cytoplasmic
EF2607-1.236ATP synthase epsilon chaincytoplasmicEF2397-1.314Elongation factor TscytoplasmicEF0228-1.380Adenylate kinasecytoplasmicEF2812-1.384Probable transcriptional regulatory proteincytoplasmicEF2866-1.384Probable transcriptional regulatory proteincytoplasmicEF0671-1.412Xa-his dipeptidasecytoplasmicEF087-1.442Elongation factor PcytoplasmicEF0453-1.605mC-Ohr family proteincytoplasmicEF0155-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0271-1.628Uncharacterized proteincytoplasmicEF0270-1.628Uncharacterized proteincytoplasmicEF0270-1.628Uncharacterized protein nusGcytoplasmicEF0270-1.628Transcription termination protein nusGcytoplasmicEF0270-1.639PTs system. mannose specific IIAB componentscytoplasmicEF0270-1.64250S ribosomal protein L7 L12cytoplasmicEF0270-1.638Transcription termination protein nusGcytoplasmicEF0270-1.64430S ribosomal protein ScytoplasmicEF0270-1.84630S ribosomal protein ScytoplasmicEF0270-1.84630S ribosomal protein ScytoplasmicEF0270-1.84630S ribosomal protein ScytoplasmicEF0270-1.84630S ribosomal protein ScytoplasmicEF0270-1.84	EF3230	-1.174	30S ribosomal protein S9	cytoplasmic
EF2397-1.314Elongation factor TscytoplasmicEF0228-1.380Adenylate kinasecytoplasmicEF2612-1.382ATP synthase subunit bcytoplasmicEF2866-1.384Probable transcriptional regulatory proteincytoplasmicEF0671-1.412Xaa-his dipeptidasecytoplasmicEF0287-1.442Elongation factor PcytoplasmicEF0471-1.412S0S ribosomal protein L1cytoplasmicEF0473-1.613Ornithine carbamoyltransferase. cataboliccytoplasmicEF0105-1.613Ornithine carbamoyltransferase. cataboliccytoplasmicEF0700-1.628Uncharacterized proteincytoplasmicEF0715-1.64250S ribosomal protein L7 L12cytoplasmicEF0709-1.689Transcription termination antitermination protein nusGcytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF2715-1.689Transcription termination antitermination protein nusGcytoplasmicEF2719-1.84630S ribosomal protein L7 L12cytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF2719-1.84630S ribosomal protein L25cytoplasmicEF2719-1.846Sitopsomal protein L25cytoplasmic <td< td=""><td>EF2607</td><td>-1.236</td><td>ATP synthase epsilon chain</td><td>cytoplasmic</td></td<>	EF2607	-1.236	ATP synthase epsilon chain	cytoplasmic
EF0228-1.380Adenylate kinasecytoplasmicEF2612-1.382ATP synthase subunit bcytoplasmicEF2663-1.384Probable transcriptional regulatory proteincytoplasmicEF0671-1.412Xaa-his dipeptidasecytoplasmicEF0671-1.442Elongation factor PcytoplasmicEF0473-1.665mc-Orh family proteincytoplasmicEF0453-1.605mc-Orh family proteincytoplasmicEF070-1.628Uncharacterized proteincytoplasmicEF070-1.628Uncharacterized protein L1cytoplasmicEF070-1.628Uncharacterized protein L7 L12cytoplasmicEF070-1.628Uncharacterized protein L7 L12cytoplasmicEF0709-1.64250S ribosomal protein L7 L12cytoplasmicEF2715-1.64250S ribosomal protein HPrcytoplasmicEF2719-1.689Transcription termination antitermination protein nusGcytoplasmicEF2719-1.689Si ribosomal protein L7 L12cytoplasmicEF2719-1.68630S ribosomal protein S8cytoplasmicEF2719-1.84630S ribosomal protein S8cytoplasmicEF2719-1.896Gls24 proteincytoplasmicEF2315-2.036Su35 YriO YrdC YwC family proteincytoplasmicEF2315-2.038Ribosome recycling factorcytoplasmicEF2315-2.038Ribosome recycling factorcytoplasmicEF2335-2.038Ribosome rotein L9c	EF2397	-1.314	Elongation factor Ts	cytoplasmic
EF2612-1.382ATP synthase subunit bcytoplasmicEF2866-1.384Probable transcriptional regulatory proteincytoplasmicEF0671-1.412Xaa-his dipeptidasecytoplasmicEF0287-1.442Elongation factor PcytoplasmicEF2718-1.462SOS ribosomal protein L1cytoplasmicEF0453-1.605mC-Ohr family proteincell membraneEF0105-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0770-1.628Uncharacterized proteincytoplasmicEF0729-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.642SOS ribosomal protein L7 L12cytoplasmicEF2729-1.889Transcription termination antitermination protein nusGcytoplasmicEF2715-1.708Phosphocarrier protein HPrcytoplasmicEF0200-1.8463OS ribosomal protein S8cytoplasmicEF2719-1.8475OS ribosomal protein S8cytoplasmicEF2219-1.866Gis24 proteincytoplasmicEF2352-2.036Sua5 YciO YwC YwC family proteincytoplasmicEF2355-2.036Sua5 YciO YwC YwC family proteincytoplasmicEF2394-2.132SOS ribosomal protein L25cytoplasmicEF352-2.036Sua5 YciO YwC YwC family proteincytoplasmicEF2355-2.036Sua5 YciO YwC YwC family proteincytoplasmicEF2394-2.117Secreted antigen, putativecytoplasmic <t< td=""><td>EF0228</td><td>-1.380</td><td>Adenylate kinase</td><td>cytoplasmic</td></t<>	EF0228	-1.380	Adenylate kinase	cytoplasmic
EF2866-1.384Probable transcriptional regulatory proteincytoplasmicEF0671-1.412Xaa-his dipeptidasecytoplasmicEF0287-1.442Elongation factor PcytoplasmicEF218-1.46850S ribosomal protein L1cytoplasmicEF0453-1.605mc-Ohr family proteincytoplasmicEF0105-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0770-1.628Uncharacterized proteincytoplasmicEF0770-1.628Uncharacterized proteincytoplasmicEF0770-1.62950S ribosomal protein L7 L12cytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF2719-1.84630S ribosomal protein L7cytoplasmicEF2719-1.84750S ribosomal protein L8cytoplasmicEF2719-1.84750S ribosomal protein L9cytoplasmicEF2825-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.039Ribosomal protein L25cytoplasmicEF2395-2.030Ribosomal protein L9cytoplasmicEF2395-2.032Ribosomal protein L9cytoplasmicEF2395-2.033Ribosomal protein L9cytoplasmicEF2395-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.033Ribosomal protein L9cytoplasmicEF2395 <td< td=""><td>EF2612</td><td>-1.382</td><td>ATP synthase subunit b</td><td>cytoplasmic</td></td<>	EF2612	-1.382	ATP synthase subunit b	cytoplasmic
EF0671-1.412Xaa-his dipeptidasecytoplasmicEF0287-1.442Elongation factor PcytoplasmicEF2718-1.46850S ribosomal protein L1cytoplasmicEF0453-1.605mc-Ohr family proteincellmembranemc-Ohr family proteincytoplasmicEF0105-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0770-1.628Uncharacterized proteincytoplasmicEF0720-1.628Uncharacterized proteincytoplasmicEF0200-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF0709-1.689Transcription termination antitermination protein nusGcytoplasmicEF0220-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84630S ribosomal protein L25cytoplasmicEF2852-2.036Suas Yci0 Ydv C YuVC family proteincytoplasmicEF235-2.038Ribosome recycling factorcytoplasmicEF235-2.038Ribosome recycling factorcytoplasmicEF334-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0039-2.132SoS ribosomal protein L9cytoplasmicEF235-2.033Ribosome recycling factorcytoplasmicEF235-2.132SoS ribosomal protein L9cytoplasmicEF235-2.132SoS ribosomal protein L9cy	EF2866	-1.384	Probable transcriptional regulatory protein	cytoplasmic
EF0287-1.442Elongation factor PcytoplasmicEF2718-1.46850S ribosomal protein L1cytoplasmicEF0453-1.605mC-Ohr family proteincell membraneEF0105-1.613Ornithine carbamoyltransferase. cataboliccytoplasmicEF0700-1.628Uncharacterized proteincytoplasmicEF0020-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF2715-1.708Phosphocarrier protein HPrcytoplasmicEF2719-1.84630S ribosomal protein S8cytoplasmicEF0709-1.846Gls24 proteincytoplasmicEF0719-1.846Gls24 proteincytoplasmicEF0220-1.89350S ribosomal protein L25cytoplasmicEF0394-2.117Secreted antigen. putativecytoplasmicEF2395-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF3034-2.117Secreted antigen. putativeextracellularEF0012-2.132Foto in Gp2cytoplasmicEF0030-2.160Gls24 proteincytoplasmicEF2925-2.033Ribosomal protein L9cytoplasmicEF2925-2.132foto in gp2cytoplasmicEF2925-2.132Cold shock domain family proteincytoplasmic	EF0671	-1.412	Xaa-his dipeptidase	cytoplasmic
EF27181.46850S ribosomal protein L1cytoplasmicEF0453-1.605mC-Ohr family proteincell membraneEF0105-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0700-1.628Uncharacterized proteincytoplasmicEF0202-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF2715-1.708Phosphocarrier proteincytoplasmicEF2719-1.84630S ribosomal protein S8cytoplasmicEF0200-1.84630S ribosomal protein L11cytoplasmicEF0219-1.84750S ribosomal protein L25cytoplasmicEF0220-1.846Sus fibosomal protein L25cytoplasmicEF0230-1.99350S ribosomal protein L25cytoplasmicEF2355-2.036Sua5 YciO YrdC YmlC family proteincytoplasmicEF2395-2.033Ribosome recycling factorcytoplasmicEF334-2.117Secreted antigen. putativeextracellularEF0012-2.132Protein Gis24 proteincytoplasmicEF0030-2.160Gis24 proteincytoplasmicEF0030-2.160Gis24 proteincytoplasmicEF0030-2.160Gis24 proteincytoplasmicEF0030-2.160Gis24 proteincytoplasmicEF0030-2.160Gis24 proteincytopl	EF0287	-1.442	Elongation factor P	cytoplasmic
EF0453-1.605mC-Ohr family proteincell membraneEF0105-1.613Ornithine carbamoyltransferase. cataboliccytoplasmicEF0700-1.628Uncharacterized proteincytoplasmicEF0020-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF0709-1.708Phosphocarrier protein HPrcytoplasmicEF2415-1.738Uncharacterized proteincytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF0709-1.738Uncharacterized proteincytoplasmicEF2719-1.84630S ribosomal protein L1cytoplasmicEF0799-1.846Gls24 proteincytoplasmicEF252-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF3394-2.117Secreted antigen. putativecytoplasmicEF0012-2.132Protein GrpEcytoplasmicEF0030-2.160Gls24 proteincytoplasmicEF0030-2.180Gls24 proteincytoplasmicEF0030-2.182Sor ibosomal protein L9cytoplasmicEF0394-2.117Secreted antigen. putativecytoplasmicEF0301-2.132Protein GrpEcytoplasmicEF0302-2.132Sor ibosomal protein L9cytoplasmic <td< td=""><td>EF2718</td><td>-1.468</td><td>50S ribosomal protein L1</td><td>cytoplasmic</td></td<>	EF2718	-1.468	50S ribosomal protein L1	cytoplasmic
EF0105-1.613Omithine carbamoyltransferase. cataboliccytoplasmicEF0770-1.628Uncharacterized proteincytoplasmicEF0020-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF2415-1.708Phosphocarrier protein HPrcytoplasmicEF2719-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84750S ribosomal protein L11cytoplasmicEF0079-1.896Gls24 proteincytoplasmicEF2719-1.896S0S ribosomal protein L25cytoplasmicEF2825-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.117Secreted antigen. putativecytoplasmicEF0020-2.132Protein GrpEcytoplasmicEF019-1.896Gls24 proteincytoplasmicEF2719-1.896Sua5 YciO YrdC YwlC family proteincytoplasmicEF2825-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2925-2.132Protein GrpEcytoplasmicEF2925-2.132SoS ribosomal protein L9cytoplasmicEF0010-2.132SoS ribosomal protein L9cytoplasmicEF0020-2.132SoS ribosomal protein L9cytoplasmicEF0020-2.132SoS ribosomal protein L9cytoplasmicEF0020-2.132SoS riboso	EF0453	-1.605	mC-Ohr family protein	cell membrane
EF0770-1.628Uncharacterized proteincytoplasmicEF0020-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF0709-1.708Phosphocarrier protein HPrcytoplasmicEF2415-1.738Uncharacterized proteincytoplasmicEF020-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84750S ribosomal protein L11cytoplasmicEF0799-1.896Gls24 proteincytoplasmicEF0799-1.896S0S ribosomal protein L25cytoplasmicEF0820-1.99350S ribosomal protein L25cytoplasmicEF2395-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0080-2.160Gls24 proteincytoplasmicEF0080-2.132SOS ribosomal protein L9cytoplasmicEF0080-2.132Cold shock domain family proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF0105	-1.613	Ornithine carbamoyltransferase. catabolic	cytoplasmic
EF0020-1.639PTS system. mannose specific IIAB componentscytoplasmicEF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF0709-1.708Phosphocarrier protein HPrcytoplasmicEF2415-1.738Uncharacterized proteincytoplasmicEF020-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84750S ribosomal protein L11cytoplasmicEF079-1.896Gls24 proteincytoplasmicEF020-1.99350S ribosomal protein L25cytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF3934-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0030-2.160Gls24 proteincytoplasmicEF0030-2.132Forein GrpEcytoplasmicEF0030-2.132SoS ribosomal protein L9cytoplasmicEF0030-2.160Gls24 proteincytoplasmicEF039-2.132SoS ribosomal protein L9cytoplasmicEF030-2.160Gls24 proteincytoplasmicEF030-2.132SoS ribosomal protein L9cytoplasmicEF030-2.132SoS ribosomal protein L9cytoplasmicEF030-2.132Gls24 proteincytoplasmicEF0305-2.233 </td <td>EF0770</td> <td>-1.628</td> <td>Uncharacterized protein</td> <td>cytoplasmic</td>	EF0770	-1.628	Uncharacterized protein	cytoplasmic
EF2715-1.64250S ribosomal protein L7 L12cytoplasmicEF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF0709-1.708Phosphocarrier protein HPrcytoplasmicEF2415-1.738Uncharacterized proteincytoplasmicEF0200-1.84630S ribosomal protein S8cytoplasmicEF0799-1.84750S ribosomal protein L11cytoplasmicEF0799-1.84750S ribosomal protein L25cytoplasmicEF0820-1.99350S ribosomal protein L25cytoplasmicEF2352-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF395-2.037Ribosome recycling factorcytoplasmicEF1307-2.132Protein GrpEcytoplasmicEF012-2.13250S ribosomal protein L9cytoplasmicEF0384-2.160Gls24 proteincytoplasmicEF0395-2.038So ribosomal protein L9cytoplasmicEF0395-2.13250S ribosomal protein L9cytoplasmicEF0395-2.132So ribosomal protein L9cytoplasmicEF0396-2.160Gls24 proteincytoplasmicEF0397-2.132So ribosomal protein L9cytoplasmicEF0398-2.160Gls24 proteincytoplasmicEF0399-2.160Gls24 proteincytoplasmicEF0390-2.160Gls24 proteincytoplasmicEF0391-2.132Cold shock domain family proteincytoplasmicEF0395-2.233	EF0020	-1.639	PTS system. mannose specific IIAB components	cytoplasmic
EF2729-1.689Transcription termination antitermination protein nusGcytoplasmicEF0709-1.708Phosphocarrier protein HPrcytoplasmicEF2415-1.738Uncharacterized proteincytoplasmicEF0220-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84750S ribosomal protein L11cytoplasmicEF0079-1.896Gls24 proteincytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF1307-2.132Protein GrpEcytoplasmicEF012-2.13250S ribosomal protein L9cytoplasmicEF2355-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF0394-2.117Secreted antigen. putativeextracellularEF0012-2.132Fotoin GrpEcytoplasmicEF0030-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF2715	-1.642	50S ribosomal protein L7 L12	cytoplasmic
EF0709-1.708Phosphocarrier protein HPrcytoplasmicEF2415-1.738Uncharacterized proteincytoplasmicEF0220-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84750S ribosomal protein L11cytoplasmicEF0790-1.896Gls24 proteincytoplasmicEF0820-1.99350S ribosomal protein L25cytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0080-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF2729	-1.689	Transcription termination antitermination protein nusG	cytoplasmic
EF2415-1.738Uncharacterized proteincytoplasmicEF0220-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84750S ribosomal protein L11cytoplasmicEF0079-1.896Gls24 proteincytoplasmicEF0820-1.99350S ribosomal protein L25cytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF1307-2.117Secreted antigen. putativeextracellularEF012-2.132Frotein GrpEcytoplasmicEF0080-2.160Gls24 proteincytoplasmicEF2925-2.203Cold shock domain family proteincytoplasmic	EF0709	-1.708	Phosphocarrier protein HPr	cytoplasmic
EF0220-1.84630S ribosomal protein S8cytoplasmicEF2719-1.84750S ribosomal protein L11cytoplasmicEF0079-1.896Gls24 proteincytoplasmicEF0820-1.99350S ribosomal protein L25cytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF0394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0800-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF2415	-1.738	Uncharacterized protein	cytoplasmic
EF2719-1.84750S ribosomal protein L11cytoplasmicEF0079-1.896Gls24 proteincytoplasmicEF0820-1.99350S ribosomal protein L25cytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF0394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF080-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF0220	-1.846	30S ribosomal protein S8	cytoplasmic
EF0079-1.896Gls24 proteincytoplasmicEF0820-1.99350S ribosomal protein L25cytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF0394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0800-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF2719	-1.847	50S ribosomal protein L11	cytoplasmic
EF0820-1.99350S ribosomal protein L25cytoplasmicEF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF0394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0800-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF0079	-1.896	Gls24 protein	cytoplasmic
EF2552-2.036Sua5 YciO YrdC YwlC family proteincytoplasmicEF2395-2.093Ribosome recycling factorcytoplasmicEF0394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0800-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF0820	-1.993	50S ribosomal protein L25	cytoplasmic
EF2395-2.093Ribosome recycling factorcytoplasmicEF0394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0080-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF2552	-2.036	Sua5 YciO YrdC YwlC family protein	cytoplasmic
EF0394-2.117Secreted antigen. putativeextracellularEF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0080-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF2395	-2.093	Ribosome recycling factor	cytoplasmic
EF1307-2.132Protein GrpEcytoplasmicEF0012-2.13250S ribosomal protein L9cytoplasmicEF0080-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF0394	-2.117	Secreted antigen. putative	extracellular
EF0012-2.13250S ribosomal protein L9cytoplasmicEF0080-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincytoplasmic	EF1307	-2.132	Protein GrpE	cytoplasmic
EF0080-2.160Gls24 proteincytoplasmicEF2925-2.233Cold shock domain family proteincvtoplasmic	EF0012	-2.132	50S ribosomal protein L9	cytoplasmic
EF2925 -2.233 Cold shock domain family protein cvtoplasmic	EF0080	-2.160	Gls24 protein	cytoplasmic
	EF2925	-2.233	Cold shock domain family protein	cytoplasmic

(Continued)

Table 3. (Continued)

Protein accession number	log2 (ΔbgsA/wt)	Annotation	Localization ^a
EF2633	-2.306	60 kDa chaperonin	cytoplasmic
EF1308	-2.341	Chaperone protein DnaK	cytoplasmic
EF0466	-2.345	Glucosamine-6-phosphate deaminase	cytoplasmic

^a Transmembrane domains were predicted with the TMHMM 2.0 algorithm [53]. Lipoproteins were classified according to Reffuveille et al. [36]. For prediction of cell wall, cytoplasmatic and extracellular proteins Locate P was used (<u>http://www.cmbi.ru.nl/locatep-db/cgi-bin/locatepdb.py</u>). For detailed data see <u>S1 Table</u>.

doi:10.1371/journal.pone.0132949.t003

membrane protein fractions from Δ bgsA and wild-type bacteria confirmed a high concentration of lipoproteins of 85% and 63%, respectively, in the extracts (data not shown). The Triton-X114 extracts from Δ bgsA induced an increased TNF- α production compared to the wild-type extracts (Fig 3). Taken together, cell membrane fractions of Δ bgsA highly enriched in lipoprotein are more potent inducers of TNF- α than those from the wild-type strain.

Inactivation of lipoprotein acylation abrogates induction of TNF- α by wild-type *E*. *faecalis* and $\Delta bgsA$

In total, 90 genes that harbor the type II signal sequence typical for lipoproteins have been identified in *E. faecalis*, representing about 2.7% of the genome [<u>36</u>]. Similar to other Grampositive bacteria, inactivation of the prolipoprotein diacylglycerol transferase (*lgt*) in *E. faecalis* causes the arrest of lipoprotein maturation at the stage of acylation of the protein, yielding non-acylated lipoproteins [<u>37,38</u>]. In *E. faecalis*, the deletion of *lgt* had no effect on bacterial morphology, growth rate, and sensitivity to sodium chloride, different pH condition, or exposure to antibiotics [<u>38</u>]. To corroborate our findings, we constructed a deletion mutant of the *lgt* gene in *E. faecalis* 12030 and created the double-deletion mutants EF 12030 $\Delta bgsA_lgt$ and EF 12030 $\Delta bgsB_lgt$. Activation of TNF- α production in macrophages stimulated with *lgt*-mutants or wild-type *E. faecalis* was analyzed (Fig 2). Similar to *S. aureus* and group B streptococci [<u>2,12,39</u>], impaired protein-lipidation in *E. faecalis* 12030 led to a reduction of macrophage activation (Fig 2). Likewise, deletion of *lgt* in $\Delta bgsB$ decreased the production of TNF- α by RAW 264.7 macrophages compared to the respective single mutant (Fig 2).



Fig 1. Altered proteins in $\Delta bgsA$ classified according to subproteomes by bioinformatic identification. Proteins significantly downregulated in $\Delta bgsA$ compared to *E. faecalis* 12030 wild type (A). Upregulated proteins in $\Delta bgsA$ compared to the wild-type (B). Transmembrane domains were predicted with the TMHMM 2.0 algorithm [53]. Lipoproteins were classified according to Reffuveille *et al.* [36]. For prediction of cell wall, cytoplasmic and extracellular proteins Locate P was used (<u>http://www.cmbi.ru.nl/locatep-db/cgi-bin/locatepdb.py</u>).

doi:10.1371/journal.pone.0132949.g001





Fig 2. Induction of TNF-α in RAW 264.7 mouse macrophages by *E. faecalis* strains. Macrophages were stimulated with live and heat-fixed bacteria at multiplicities of infection (MOI) as indicated (A and B) or with cell-free, dialyzed *E. faecalis* supernatants (C). RAW 264.7 macrophages were seeded at a density of 1 x 10⁵ cells/ml in 24-well dishes in endotoxin-free DMEM containing 10% fetal calf serum. Cultures were stimulated at 37°C in a 5% humidified CO₂ environment for 3 h (A) and 16 h (B), respectively, and supernatant from macrophage culture was analyzed for TNF-α by ELISA. The strains used for stimulation are indicated in the legend. LPS was used as positive control. Data represent mean ± SEM of triplicates. ND = not detected. * $p < 0.001 12030 \Delta bgsA$ versus 12030 WT, ** $p < 0.001 12030 \Delta bgsA$ versus 12030 MT, ** $p < 0.001 12030 \Delta bgsA$ versus 12030 $\Delta bgsA$ versus 0.001 12030 $\Delta bgsA$ versus 0.001 versus 0.001 v

doi:10.1371/journal.pone.0132949.g002





Fig 3. Stimulation of TNF- α production in RAW 264.7 mouse macrophages by lipoprotein-enriched cell membrane fractions of *E. faecalis* wild type and $\Delta bgsA$. RAW 264.7 cells were incubated with lipoprotein-enriched Triton X-114 extracts from total membrane protein fractions derived from the indicated *E. faecalis* strains. The concentration of lipoprotein extracts was measured photometrically and normalized to a bacterial cfu:RAW 264.7 cell ratio of 10,000:1. At 16 h, supernatants were collected and TNF- α concentrations were quantified by ELISA. LPS at a concentration of 100 ng/ml was used as positive control. Data represent mean ± SEM of triplicates. * p < 0.001 12030 $\Delta bgsA$ versus 12030 WT.

doi:10.1371/journal.pone.0132949.g003

Inactivation of the *lgt*-gene in $\Delta bgsA$ had even stronger effects on TNF- α production in the RAW 264.7 macrophage activation assay if culture supernatant was used as stimulant (Fig.2).

ΔbgsA induces a strong activation of TLR2

Next, we wanted to identify the cognate receptor for lipoproteins in $\Delta bgsA$. To this end, wildtype bacteria, $\Delta bgsA$ and $\Delta bgsB$ were analyzed for NF- κ B activation in a NF- κ B-dependent luciferase reporter assay in epithelial cells (HEK 293) that stably express the human TLR2 receptor [40]. Whole *E. faecalis* wild-type bacteria did not activate NF- κ B even at high concentrations (Fig 4). In contrast, $\Delta bgsA$ induced NF- κ B activation at concentrations as low as 1 µg/ ml (dry weight). $\Delta bgsB$ also induced NF- κ B, but was a less potent stimulus than $\Delta bgsA$ (Fig 4). Dialyzed, cell-free bacterial cell culture supernatant of wild-type bacteria also did not induce NF- κ B activation, while supernatant from $\Delta bgsA$ was a strong inducer. Cells were also stimulated with bacterial cell envelope compounds extracted by the Bligh-Dyer method. This method extracts lipids and lipid-containing biomolecules from bacterial or eukaryotic cells [41]. Again, extracts of $\Delta bgsA$ but not of the wild-type stimulated TLR2 activation (Fig 4). Compared to whole bacterial cells, cell culture supernatant and lipophilic antigens extracts were about 10-fold less potent agonists of the TLR2 receptor (Fig 4). These data establish that *E. faecalis* $\Delta bgsA$ cells and its culture supernatant contain higher levels of TLR2 agonists compared to wild-type bacteria.





Fig 4. Stimulation of HEK-TLR2 cells transfected with an NF- κ B-dependent ELAM-luciferase reporter gene with *E. faecalis* antigens. HEK cells were stimulated for 6 h with escalating antigen concentrations as indicated, lysed and luciferase activity was determined by luminometry. The concentration of bacterial cells is expressed as dry weight per ml. Fold-induction denotes stimulated versus non-stimulated luciferase activity. Stimulation with whole bacterial cells (A). Stimulation with dialyzed cell-free culture supernatant (B). Stimulation with *E. faecalis* cell membrane total lipid extracts (C). Data are expressed as mean ± SEM of triplicates. ND = not detected. * p < 0.001 12030 $\Delta bgsA$ versus 12030 WT, ** p < 0.001 12030 $\Delta bgsA$ versus 12030 $\Delta bgsB$, *** p < 0.001 12030 $\Delta bgsB$ versus 12030 wild type by 2-way ANOVA with Bonferroni post-test for pairwise comparisons.

doi:10.1371/journal.pone.0132949.g004

Inactivation of bgsA enhances virulence in a mouse bacteremia model

TLR-mediated activation of cellular innate immunity during infection is tightly regulated, since over- and underactivation can have detrimental consequences to the host. Given the strong engagement of TLR2 by $\Delta bgsA$, we were interested in the effects of the deletion of *bgsA* on enterococcal virulence in a mouse peritonitis model. The LD50 in this model is 5.0 x 10⁹ bacteria, reflecting the relatively low virulence of *E. faecalis* in vivo [22]. For the mouse peritonitis model we employed a bacterial dose slightly below the LD50. One of 14 mice died after infection with 1.3 x 10⁹ wild-type bacteria (Fig.5). In contrast, the same inoculum of $\Delta bgsA$ killed 10 of 14 mice within 24 h (p = 0.0096). There were no subsequent deaths (total observation time five days). No significant difference in mortality between mice infected with $\Delta bgsB$ and those infected with wild-type *E. faecalis* was observed (Fig.5A). We repeated the experiment at a lower inoculum of 3 x 10⁸ bacteria per mouse. With this lower dose, 2 of 8 mice infected with $\Delta bgsA$ died within the observation period (5 days), while all mice infected with the wild-type survived (p = 0.14).

Peritonitis caused by EF12030 $\Delta bgsA$ is associated with increased proinflammatory cytokines

To better understand excess mortality in peritonitis induced by $\Delta bgsA$, we infected mice with an inoculum similar to that used in the survival model (2.0 x 10⁹) and quantified the bacterial concentration in the peritoneal cavity, blood, and kidneys at 3 and 12 hours after infection (Fig 5B). No significant difference in bacterial load was noted at corresponding time points. Thus, $\Delta bgsA$ does not appear to impede bacterial clearance during peritonitis, and differences in bacterial load cannot explain the differences in mortality.

We also measured leukocytes and inflammatory cytokines during *E. faecalis* peritonitis. Three hours after infection, more leukocytes were recruited to the peritoneal cavity in animals infected with $\Delta bgsA$ than in those infected with wild-type bacteria or $\Delta bgsB$ (Fig 6). To Α



Fig 5. Survival and bacterial load of BALB/c mice after intraperitoneal infection with *E. faecalis* strains. Survival after infection with $1.3 \times 10^9 E$. *faecalis*. P = 0.0096 EF 12030 wild-type vs. $\Delta bgsA$ determined by the log-rank test (A). Bacterial counts 3 h and 12 h after i.p. challenge (inoculum 2.0 x 10^9 cfu per mouse, 14 mice per group). The bacterial load is expressed as the log₁₀ (cfu) per ml ± SEM (B). P > 0.05 EF 12030 wild-type vs. $\Delta bgsA$ vs. $\Delta bgsB$ at 3 h and 12 h by 2-way ANOVA.

doi:10.1371/journal.pone.0132949.g005

determine whether a dysregulated inflammatory response was involved in the increased mortality caused by $\Delta bgsA$, we measured cytokine concentrations in the peritoneal fluid and blood. One hour after infection with $\Delta bgsA$, plasma concentrations of TNF- α , IL-6, and MIP-2 were significantly increased in mice infected with $\Delta bgsA$ as compared to mice infected with wildtype bacteria or $\Delta bgsB$ (Fig 7). Infection with $\Delta bgsA$ resulted also in significantly increased TNF- α concentrations in the peritoneal lavage fluid 3 h after infection compared to mice with peritonitis caused by wild-type bacteria or $\Delta bgsB$ (Fig 6B). At 12 h after infection, the kinetics of TNF- α production in the peritoneum had reversed: while low amounts of TNF- α were found in mice infected with $\Delta bgsA$, mice infected with the wild-type strain or $\Delta bgsB$ displayed





Fig 6. Leukocyte count and TNF- α expression in the PLF 1, 3, and 12 h after intraperitoneal infection with *E. faecalis* strains. Number of leukocytes in the PLF (A). TNF- α in the PLF (B). * p < 0.05, ** p < 0.001, by 2-way ANOVA. Data represent means ± SEM of individual mice (8 mice per group).

doi:10.1371/journal.pone.0132949.g006

elevated levels of this cytokine (Fig 6B). These results show a correlation between mortality caused by $\Delta bgsA$ and increased production of inflammatory cytokines at early time points.

Discussion

Our current work demonstrates the consequences of a disturbed cell membrane glycolipid homeostasis on the expression of lipoproteins in the cell envelope and the activation of the innate immune system by *E. faecalis*. Inactivation of the *bgsA* gene in *E. faecalis* led to a more than 3-fold higher lipoprotein-content in $\Delta bgsA$ compared to wild-type bacteria. $\Delta bgsA$ antigens were more potent activators of mouse macrophages and much stronger agonists of the TLR2 receptor. Genetic inactivation of the biosynthesis of lipoprotein strongly reduced the potency of $\Delta bgsA$ to stimulate macrophages. Conversely, lipoprotein-enriched Triton X114 extracts from total membrane fractions of $\Delta bgsA$ were stronger activators of mouse macrophages than wild type extracts. The alteration of the cell-surface proteome by inactivation of *bgsA* also enhanced the virulence of *E. faecalis* in a mouse peritonitis model.

Immune recognition of enterococci during mouse peritonitis has been described in detail by Leendertse and coworkers [20,22]. Peritoneal infection by *Enterococcus faecium* is sensed predominantly by macrophages via TLR2 which then secrete IL6, TNF- α , MIP-2, and KC during early infection [20,22]. A consecutive influx of neutrophils into the peritoneal cavity then leads to the clearance of the bacteria [20,22]. Working with an infection model similar to the one used by Leendertse, we were able to examine the consequences of overstimulation of the TLR2 system on the natural course of peritoneal infection. Peritonitis due to $\Delta bgsA$ led to an excessive induction of TNF- α , IL6, and MIP-2 accompanied by a higher influx of leukocytes in the peritoneum and to increased mortality of infected mice. Our results confirm previous studies which have shown that the overproduction of chemokines such as MIP-2 contributes to mortality in animal models of polymicrobial sepsis [42–44].

It is interesting that the effects of the inactivation of *bgsA* and a de-repressed lipoprotein production on the virulence of *E. faecalis* are highly dependent on the type of infection. We reported previously that inactivation of *bgsA* reduces biofilm formation and adherence to colonic cells, while the mutation improves the ability of *E. faecalis* to colonize the urinary tract [15,45]. In a mouse bacteremia model, $\Delta bgsA$ was cleared more rapidly from the bloodstream than the wild-type strain [15]. Yet during peritoneal infection as reported here, inactivation of bgsA induced stronger inflammation and led to higher mortality. Because of the pleiotropic phenotype of $\Delta bgsA$, these results have to be interpreted with caution [15]. Nevertheless, repression of lipoprotein production by bgsA may be advantageous in some host compartments to escape detection by the host immune system while in others, like the peritoneum, virulence is suppressed. Since colonization of the gastrointestinal tract is the default ecological niche of E. faecalis, repression of lipoprotein production by bgsA probably improves overall fitness by evasion of the mucosal immune system. A similar strategy to subvert recognition by the innate immune system has been described by the intracellular pathogen *Francisella novicida* [46]. The F. novicida protein FTN 0757 specifically represses the production of its lipoprotein FTN_1103 and deletion of FTN_0757 leads to stronger stimulation of TLR2 and induction of higher levels of inflammatory cytokines compared to wild-type bacteria [46]. Hence, FTN 0757 was suggested to function as an immune escape mechanism in F. novicida. Furthermore, in S. aureus, capsule expression and formation of small colony variants has been described as a means to downregulate TLR2 activation [47]

Our study does not reveal a clear mechanism how the glycolipid mix of the cell membrane leads to an upregulation of lipoprotein concentration. Studies on the role of glycolipids in membrane physiology, however, point to secondary adjustments of the lipid composition in $\Delta bgsA$ to restore cell membrane homeostasis [48]. The biophysical properties of membrane lipids are determined by the size of their polar head groups in relation to the hydrophobic acylglycerol backbone. MGlcDAG with its smaller polar head group forms inverted nonlamellar structures as opposed to the bilayer conformation of DGlcDAG [49]. This results in a larger negative curvature and increased bilayer curvature stress for membranes composed of MGlcDAG as compared to DGlcDAG [49]. Cell membranes of $\Delta bgsA$ only contain MGlcDAG and the presence of additional, bilayer forming amphiphiles are most likely needed to dilute the concentration of the non-bilayer forming glycolipid. In Streptococcus pneumoniae, for example, deletion of glycosyltransferase cpoA leads to an arrest of the synthesis of galactosylglucosyl-diacylglycerol and to a secondary increase in the proportion of phosphatidylglycerol to cardiolipin [50]. Lipoproteins also contain large polar head groups and could potentially act as bilayer-prone amphiphiles in the cell membrane of *AbgsA*. Studies in Acholeplasma laidlawii suggest that the activities of the interfacial glycosyltransferases that synthesize MGlcDAG and





doi:10.1371/journal.pone.0132949.g007

DGlcDAG are regulated by the physical properties of the membrane containing their substrates [48,51]. Hence, biochemical regulation possibly also governs the compensatory increase of synthesis of lipoproteins in $\Delta bgsA$. This model could also explain why inactivation of $\Delta bgsB$ does not cause enhanced activation of the innate immunity or promotes virulence in peritonitis. Mutation of *bgsB* in *E. faecalis* causes a complete arrest of glycolipid synthesis [25] and the mutant therefore does not overproduce toxic non-bilayer forming glycolipids. Hence, fewer adaptive changes to the cell envelope maybe needed to maintain membrane homeostasis.

Another question raised by our study is, if TLR2 activation by $\Delta bgsA$ is mediated by a global upregulation of lipoproteins or by one or more specific lipoproteins that act as dominant inducers of TLR2. Upregulation clearly affected lipoproteins unevenly in $\Delta bgsA$. While a total of 12 lipoproteins were upregulated between 0.19 and 3.11-fold compared to wild-type levels, the expression of EF3041 was increased over 12-fold. Theoretical considerations as well as experimental studies, however, do not support the theory that certain lipoproteins act as dominant inducers of TLR2. Modeling studies of the crystallized structures of the TLR2-TLR6-lipopeptide complex suggest that TLR2 activation by lipopeptides is mediated only by a small and highly conserved structural motif of two ester-bound acyl-chains of at least 12 carbons each and the first two N-terminal amino acids of the polypeptide chain [52]. According to this model, the structure of the polypeptide chain beyond the second amino acid is negligible for the potency of Iipopeptide or lipoprotein to engage TLR2. Furthermore, in vitro studies of the *FTN_0757* deletion mutant in *F. novicida* show that equimolar concentrations of Iipoproteins from the wild-type strain and ΔFTN_0757 had a similar potency as TLR2 activators [46].

Taken together, our findings reveal an intimate interplay between the concentration of the bilayer-forming glycolipid DGlcDAG, the expression of lipoproteins, and activation of the host immune system. We show that deletion of *bgsA* leads to upregulation of bacterial lipoproteins and strongly enhances host inflammatory response and virulence in enterococcal peritonitis.

Supporting Information

S1 Table. List of identified proteins by proteomic analysis. The table includes all protein quantification data in "summary"-tab as well as the number of peptides identified in each single analysis in the tabs WT 1/2/3 and *bgsA* 1/2/3. Protein identifications were considered significant for the biological system if the protein was identified in at least two out of three samples in wild type or the mutant. (XLSX)

S2 Table. List of proteins quantified by spectral abundance factors. (XLSX)

Acknowledgments

We are grateful to Ioana Toma, Türkan Sankic, and Dominik Anders for expert technical assistance. We would also like to thank Otto Holst for helpful discussions.

Author Contributions

Conceived and designed the experiments: CT AKD IS YB AO JH PH DB. Performed the experiments: CT AKD IS DW YB KH MB. Analyzed the data: CT AKD AO IS PH DB JH. Wrote the paper: CT AKD PH JH.

References

- 1. Mogensen TH (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22: 240–273. doi: 10.1128/CMR.00046-08 PMID: 19366914
- Henneke P, Dramsi S, Mancuso G, Chraibi K, Pellegrini E, Theilacker C, et al. (2008) Lipoproteins are critical TLR2 activating toxins in group B streptococcal sepsis. J Immunol 180: 6149–6158. PMID: <u>18424736</u>
- Knapp S, Wieland CW, van 't Veer C, Takeuchi O, Akira S, Florquin S, et al. (2004) Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 172: 3132–3138. PMID: <u>14978119</u>
- Yimin, Kohanawa M, Zhao S, Ozaki M, Haga S, Nan G, et al. (2013) Contribution of Toll-Like Receptor 2 to the Innate Response against *Staphylococcus aureus* Infection in Mice. PLoS ONE 8: e74287. doi: 10.1371/journal.pone.0074287 PMID: 24058538
- Echchannaoui H, Frei K, Schnell C, Leib SL, Zimmerli W, Landmann R (2002) Toll-like receptor 2-deficient mice are highly susceptible to *Streptococcus pneumoniae* meningitis because of reduced bacterial clearing and enhanced inflammation. J Infect Dis 186: 798–806. doi: <u>10.1086/342845</u> PMID: <u>12198614</u>
- Mancuso G, Midiri A, Beninati C, Biondo C, Galbo R, Akira S, et al. (2004) Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease. J Immunol 172: 6324–6329. PMID: 15128822
- Brouwer MC, de Gans J, Heckenberg SGB, Zwinderman AH, Van Der Poll T, van de Beek D (2009) Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 9: 31–44. doi: <u>10.1016/S1473-3099(08)70261-5</u> PMID: <u>19036641</u>
- Casanova J-L, Abel L, Quintana-Murci L (2011) Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 29: 447–491. doi: 10.1146/annurev-immunol-030409-101335 PMID: 21219179
- 9. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373–384. doi: 10.1038/ni.1863 PMID: 20404851
- Zähringer U, Lindner B, Inamura S, Heine H, Alexander C (2008) TLR2—promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213: 205– 224. doi: <u>10.1016/j.imbio.2008.02.005</u> PMID: <u>18406368</u>
- Hashimoto M, Tawaratsumida K, Kariya H, Kiyohara A, Suda Y, Krikae F, et al. (2006) Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in *Staphylococcus aureus*. J Immunol 177: 3162–3169. PMID: <u>16920954</u>
- Stoll H, Dengjel J, Nerz C, Götz F (2005) Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect Immun 73: 2411–2423. doi: <u>10.1128/IAI.73.</u> <u>4.2411-2423.2005</u> PMID: <u>15784587</u>
- Prados-Rosales R, Baena A, Martinez LR, Luque-Garcia J, Kalscheuer R, Veeraraghavan U, et al. (2011) Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2dependent manner in mice. J Clin Invest 121: 1471–1483. doi: 10.1172/JCI44261 PMID: 21364279
- Gurung M, Moon DC, Choi CW, Lee JH, Bae YC, Kim J, et al. (2011) Staphylococcus aureus produces membrane-derived vesicles that induce host cell death. PLoS ONE 6: e27958. doi: <u>10.1371/journal.</u> pone.0027958 PMID: 22114730
- Theilacker C, Sanchez-Carballo P, Toma I, Fabretti F, Sava I, Kropec A, et al. (2009) Glycolipids are involved in biofilm accumulation and prolonged bacteraemia in *Enterococcus faecalis*. Mol Microbiol 71: 1055–1069. doi: <u>10.1111/j.1365-2958.2009.06587.x</u> PMID: <u>19170884</u>

- 16. Theilacker C, Sava I, Sanchez-Carballo P, Bao Y, Kropec A, Grohmann E, et al. (2011) Deletion of the glycosyltransferase bgsB of Enterococcus faecalis leads to a complete loss of glycolipids from the cell membrane and to impaired biofilm formation. BMC Microbiol 11: 67. doi: <u>10.1186/1471-2180-11-67</u> PMID: <u>21470413</u>
- Edman M, Berg S, Storm P, Wikström M, Vikström S, Ohman A, et al. (2003) Structural features of glycosyltransferases synthesizing major bilayer and nonbilayer-prone membrane lipids in *Acholeplasma laidlawii* and *Streptococcus pneumoniae*. J Biol Chem 278: 8420–8428. doi: <u>10.1074/jbc.M211492200</u> PMID: <u>12464611</u>
- Wikström M, Xie J, Bogdanov M, Mileykovskaya E, Heacock P, Wislander A, et al. (2004) Monoglucosyldiacylglycerol, a foreign lipid, can substitute for phosphatidylethanolamine in essential membraneassociated functions in *Escherichia coli*. J Biol Chem 279: 10484–10493. doi: <u>10.1074/jbc</u>. M310183200 PMID: 14688287
- Leendertse M, Willems RJL, Giebelen IAJ, Roelofs JJTH, Bonten MJM, van der Poll T (2009) Neutrophils are essential for rapid clearance of *Enterococcus faecium* in mice. Infect Immun 77: 485–491. doi: 10.1128/IAI.00863-08 PMID: 19001080
- Leendertse M, Willems RJL, Giebelen IAJ, Roelofs JJTH, Van Rooijen N, Bonten MJM, et al. (2009) Peritoneal macrophages are important for the early containment of Enterococcus faecium peritonitis in mice. Innate Immunity 15: 3–12. doi: 10.1177/1753425908100238 PMID: 19201820
- Leendertse M, Willems RJL, Flierman R, de Vos AF, Bonten MJM, van der Poll T (2010) The complement system facilitates clearance of *Enterococcus faecium* during murine peritonitis. J Infect Dis 201: 544–552. doi: 10.1086/650341 PMID: 20064073
- Leendertse M, Willems RJL, Giebelen IAJ, van den Pangaart PS, Wiersinga WJ, de Vos AF, et al. (2008) TLR2-dependent MyD88 signaling contributes to early host defense in murine *Enterococcus faecium* peritonitis. J Immunol 180: 4865–4874. PMID: <u>18354210</u>
- Paoletti LC, Ross RA, Johnson KD (1996) Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide. Infect Immun 64: 1220–1226. PMID: 8606082
- Cieslewicz MJ, Kasper DL, Wang Y, Wessels MR (2001) Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem 276: 139–146. doi: <u>10.1074/jbc.M005702200</u> PMID: <u>11027683</u>
- Bychowska A, Theilacker C, Czerwicka M, Marszewska K, Huebner J, Holst O, et al. (2011) Chemical structure of wall teichoic acid isolated from *Enterococcus faecium* strain U0317. Carbohydr Res 346: 2816–2819. doi: <u>10.1016/j.carres.2011.09.026</u> PMID: <u>22024569</u>
- Brusca JS, Radolf JD (1994) Isolation of integral membrane proteins by phase partitioning with Triton X-114. Meth Enzymol 228: 182–193. PMID: <u>8047007</u>
- Hashimoto M, Tawaratsumida K, Kariya H, Aoyama K, Tamura T, Suda Y (2006) Lipoprotein is a predominant Toll-like receptor 2 ligand in *Staphylococcus aureus* cell wall components. Int Immunol 18: 355–362. doi: 10.1093/intimm/dxh374 PMID: 16373361
- Becher D, Hempel K, Sievers S, Zühlke D, Pané-Farré J, Otto A, et al. (2009) A proteomic view of an important human pathogen—towards the quantification of the entire *Staphylococcus aureus* proteome. PLoS ONE 4: e8176. doi: <u>10.1371/journal.pone.0008176</u> PMID: <u>19997597</u>
- Dreisbach A, Otto A, Becher D, Hammer E, Teumer A, Gouw JW, et al. (2008) Monitoring of changes in the membrane proteome during stationary phase adaptation of *Bacillus subtilis* using in vivo labeling techniques. Proteomics 8: 2062–2076. doi: 10.1002/pmic.200701081 PMID: 18491319
- Otto A, Bernhardt J, Meyer H, Schaffer M, Herbst F-A, Siebourg J, et al. (2010) Systems-wide temporal proteomic profiling in glucose-starved *Bacillus subtilis*. Nat Commun 1: 137. doi: <u>10.1038/</u> <u>ncomms1137</u> PMID: <u>21266987</u>
- MacCoss MJ, Wu CC, Liu H, Sadygov R, Yates JR (2003) A correlation algorithm for the automated quantitative analysis of shotgun proteomics data. Analytical chemistry 75: 6912–6921. doi: <u>10.1021/</u> <u>ac034790h</u> PMID: <u>14670053</u>
- Park SK, Venable JD, Xu T, Yates JR (2008) A quantitative analysis software tool for mass spectrometry-based proteomics. Nat Methods 5: 319–322. doi: <u>10.1038/nmeth.1195</u> PMID: <u>18345006</u>
- Zybailov B, Mosley AL, Sardiu ME, Coleman MK, Florens L, Washburn MP (2006) Statistical analysis of membrane proteome expression changes in *Saccharomyces cerevisiae*. J Proteome Res 5: 2339– 2347. doi: <u>10.1021/pr060161n</u> PMID: <u>16944946</u>
- Zhang Y, Wen Z, Washburn MP, Florens L (2010) Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. 82: 2272–2281. Anal Chem 82:2272–2281. doi: 10.1021/ac9023999 PMID: 20166708

- Sievers S, Ernst CM, Geiger T, Hecker M, Wolz C, Becher D, et al. (2010) Changing the phospholipid composition of *Staphylococcus aureus* causes distinct changes in membrane proteome and membrane-sensory regulators. Proteomics 10: 1685–1693. doi: <u>10.1002/pmic.200900772</u> PMID: <u>20162562</u>
- Reffuveille F, Leneveu C, Chevalier S, Auffray Y, Rincé A (2011) Lipoproteins of *Enterococcus faecalis*: bioinformatic identification, expression analysis and relation to virulence. Microbiology 157: 3001– 3013. doi: 10.1099/mic.0.053314-0 PMID: 21903750
- Hutchings MI, Palmer T, Harrington DJ, Sutcliffe IC (2009) Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold "em, knowing when to fold"em. 17: 13–21. doi: <u>10.1016/j.tim.2008.10.001</u>
- Reffuveille F, Serror P, Chevalier S, Budin-Verneuil A, Ladjouzi R, Bernay B, et al. (2012) The prolipoprotein diacylglyceryl transferase (Lgt) of *Enterococcus faecalis* contributes to virulence. Microbiology 158: 816–825. doi: <u>10.1099/mic.0.055319-0</u> PMID: <u>22135097</u>
- Bubeck Wardenburg J, Williams WA, Missiakas D (2006) Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc Natl Acad Sci USA 103: 13831– 13836. doi: 10.1073/pnas.0603072103 PMID: 16954184
- Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, et al. (2005) Role of lipoteichoic acid in the phagocyte response to group B Streptococcus. J Immunol 174: 6449–6455. PMID: <u>15879147</u>
- Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911–917. PMID: <u>13671378</u>
- Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL (1997) Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect Immun 65: 3847–3851. PMID: <u>9284162</u>
- 43. Wengner AM, Pitchford SC, Furze RC, Rankin SM (2008) The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation. Blood 111: 42–49. doi: <u>10.</u> <u>1182/blood-2007-07-099648</u> PMID: <u>17928531</u>
- Ness TL, Hogaboam CM, Strieter RM, Kunkel SL (2003) Immunomodulatory role of CXCR2 during experimental septic peritonitis. J Immunol 171: 3775–3784. PMID: <u>14500678</u>
- 45. Diederich AK, Wobser D, Spiess M Sava IG, Huebner J, Sakinc T (2014) Role of glycolipids in the pathogenesis of *Enterococcus faecalis* urinary tract infection. Plos One 9: e96295. doi: <u>10.1371/journal.</u> <u>pone.0096295</u> PMID: 24806450
- 46. Jones CL, Sampson TR, Nakaya HI, Pulendran B, Weiss DS (2012) Repression of bacterial lipoprotein production by *Francisella novicida* facilitates evasion of innate immune recognition. Cell Microbiol 14: 1531–1543. doi: 10.1111/j.1462-5822.2012.01816.x PMID: 22632124
- Hilmi D, Parcina M, Stollewerk D, Ostrop J, Josten M, Meilaender A, et al. (2014) Heterogeneity of host TLR2 stimulation by *Staphylocoocus aureus* isolates. PLoS ONE 9: e96416. doi: <u>10.1371/journal.</u> <u>pone.0096416</u> PMID: <u>24810614</u>
- Parsons JB, Rock CO (2013) Bacterial lipids: metabolism and membrane homeostasis. Prog Lipid Res 52: 249–276. doi: <u>10.1016/j.plipres.2013.02.002</u> PMID: <u>23500459</u>
- 49. Jouhet J (2013) Importance of the hexagonal lipid phase in biological membrane organization. Front Plant Sci 4: 494. doi: <u>10.3389/fpls.2013.00494</u> PMID: <u>24348497</u>
- Meiers M, Volz C, Eisel J, Maurer P, Henrich B, Hakenbeck R (2014) Altered lipid composition in *Streptococcus pneumoniae* cpoA mutants. BMC Microbiol 14: 12. doi: <u>10.1186/1471-2180-14-12</u> PMID: <u>24443834</u>
- Lind J, Rämö T, Klement MLR, Bárány-Wallje E, Epand RM, Epand RF, et al. (2007) High cationic charge and bilayer interface-binding helices in a regulatory lipid glycosyltransferase. Biochemistry 46: 5664–5677. doi: 10.1021/bi700042x PMID: 17444657
- Kang JY, Nan X, Jin MS, Youn S-J, Ryu YH, Mah S, et al. (2009) Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31: 873–884. doi: <u>10.1016/j.immuni.</u> 2009.09.018 PMID: 19931471
- Krogh A, Larsson B, von Heijne G, Sonnhammer ELL (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. (2001) J Mol Biol. 305: 567–580. doi: <u>10.1006/jmbi.2000.4315</u> PMID: <u>11152613</u>
- 54. Huebner J, Wang Y, Krueger WA, Madoff LC, Martirosian G, Boisot S, et al. (1999) Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of *Enterococcus faecalis* and vancomycin-resistant *Enterococcus faecium*. Infect Immun 67: 1213–1219. PMID: 10024563
- Callegan MC, Jett BD, Hancock LE, Gilmore MS (1999) Role of hemolysin BL in the pathogenesis of extraintestinal *Bacillus cereus* infection assessed in an endophthalmitis model. Infect Immun 67: 3357–3366. PMID: <u>10377113</u>